[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2220
1. Wong JC, Raman S: Surgical resectability of pancreatic adenocarcinoma: CTA. Abdom Imaging; 2010 Aug;35(4):471-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resectability of pancreatic adenocarcinoma: CTA.
  • Imaging studies play an important role in the diagnosis and management of patients with pancreatic adenocarcinoma.
  • Meticulous technique following a well-designed pancreas protocol is essential for maximizing the diagnostic efficacy of CT.
  • After the diagnosis of pancreatic adenocarcinoma is made, the key to management is staging to determine resectability.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1999 Nov;213(2):468-72 [10551228.001]
  • [Cites] Radiology. 2009 Mar;250(3):758-65 [19164113.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]
  • [Cites] J Comput Assist Tomogr. 2001 May-Jun;25(3):337-42 [11351180.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] AJR Am J Roentgenol. 2002 Apr;178(4):821-6 [11906855.001]
  • [Cites] J Gastrointest Surg. 2001 Nov-Dec;5(6):626-33 [12086901.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1217-24 [12704026.001]
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] AJR Am J Roentgenol. 1988 May;150(5):1035-41 [3258703.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]
  • [Cites] Abdom Imaging. 1996 May-Jun;21(3):202-6 [8661548.001]
  • [Cites] AJR Am J Roentgenol. 1997 Apr;168(4):971-7 [9124153.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Radiology. 1999 Jan;210(1):71-4 [9885589.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10):753-63 [15545675.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):349-64 [16549332.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1513-20 [17114545.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):738-44 [17580363.001]
  • [Cites] AJR Am J Roentgenol. 2007 Nov;189(5):1044-50 [17954638.001]
  • [Cites] Radiographics. 2007 Nov-Dec;27(6):1653-66 [18025509.001]
  • [Cites] Radiology. 2007 Dec;245(3):770-8 [17951353.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):111-25 [18272835.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1509-12 [10584793.001]
  • (PMID = 19468791.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2900587
  •  go-up   go-down


2. D'Onofrio M, Vecchiato F, Gallotti A, Falconi M, Capelli P, Pozzi Mucelli R: Small undifferentiated pancreatic adenocarcinoma which mimics IPMN at imaging. JOP; 2009;10(4):406-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small undifferentiated pancreatic adenocarcinoma which mimics IPMN at imaging.
  • CONTEXT: To present the case of an unusual presentation at imaging of a very small solid undifferentiated pancreatic adenocarcinoma which mimics a side-branch intraductal papillary mucinous neoplasm.
  • CASE REPORT: The patient came to our hospital for a revaluation of a cystic pancreatic lesion.
  • A small cystic lesion of about 1.5 cm in diameter was seen in the posterior aspect of the pancreatic uncinate process A very small, solid, vascularized nodule was detected at CEUS within the lesion.
  • MRI confirmed the presence of an intralesional nodule and communication with the main pancreatic duct was demonstrated, suggesting the diagnosis of intraductal papillary mucinous neoplasm with solid intralesional tissue.
  • An undifferentiated adenocarcinoma having a notable peripheral inflammatory reaction and dilated branch duct was finally diagnosed.
  • CONCLUSION: To our knowledge, we present for the first time, the case of a very small solid undifferentiated pancreatic adenocarcinoma of the uncinate process which mimicked a side-branch intraductal papillary mucinous neoplasm at imaging.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581744.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Chan M, Scaife C, Thaker HM, Adler DG: Adenocarcinoma of the pancreas undetected by multidetector CT, endoscopic ultrasound, or intraoperative ultrasound. JOP; 2009;10(5):554-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the pancreas undetected by multidetector CT, endoscopic ultrasound, or intraoperative ultrasound.
  • CONTEXT: Patients with known or suspected pancreatic adenocarcinoma are typically evaluated with noninvasive imaging studies and endoscopic ultrasound.
  • Some patients have pancreatic adenocarcinomas that cannot be detected using any of these methods.
  • Multiple endoscopic ultrasound and triple phase pancreatic protocol CT exams were negative for a mass lesion and revealed a normal pancreas.
  • Intraoperative ultrasound of the pancreas was also felt to be normal.
  • Intraoperative biopsy of the head of the pancreas revealed a small, moderately to poorly differentiated adenocarcinoma, not visible on any of her imaging studies.
  • CONCLUSION: Some pancreatic adenocarcinomas may defy detection using modern imaging modalities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Errors. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Cholangiopancreatography, Endoscopic Retrograde / methods. Delayed Diagnosis. Endosonography / methods. Female. Humans. Intraoperative Period. Middle Aged. Tomography, X-Ray Computed / methods. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734637.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


Advertisement
4. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB: Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg; 2007 Jul;246(1):52-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
  • OBJECTIVE: To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma.
  • Standard pathologic evaluation of the PD specimen included permanent section analysis of the final bile duct, pancreatic, and superior mesenteric artery (SMA) margins.
  • Survival and follow-up were calculated from the date of initial histologic diagnosis to the dates of first recurrence or death and last contact, respectively.
  • RESULTS: PD was performed on 360 consecutive patients with pancreatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chir Ital. 2000 May-Jun;52(3):263-70 [10932371.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):47-55 [11420482.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2537-44 [12011133.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1311-23 [12704043.001]
  • [Cites] Eur J Surg Oncol. 1991 Apr;17(2):173-81 [2015922.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Br J Surg. 1996 May;83(5):625-31 [8689203.001]
  • [Cites] Pancreas. 1996 May;12(4):373-80 [8740405.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):39-49 [9300738.001]
  • [Cites] Am Surg. 1999 Jul;65(7):618-23; discussion 623-4 [10399969.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1232-7 [16804874.001]
  • [CommentIn] Ann Surg. 2008 Apr;247(4):716-7 [18362643.001]
  • (PMID = 17592291.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA101936; United States / NCI NIH HHS / CA / 1 P20 CA101936-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1899216
  •  go-up   go-down


5. Khosravi Shahi P, Díaz Muñoz de la Espada VM: [Pancreatic adenocarcinoma: therapeutical update]. An Med Interna; 2005 Aug;22(8):390-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic adenocarcinoma: therapeutical update].
  • [Transliterated title] Adenocarcinoma de páncreas: actualizaciones terapéuticas.
  • Cancer of the exocrine pancreas continues to be a major unsolved health problem.
  • Because of difficulties in diagnosis, the aggressiveness of pancreatic cancers, and the lack of effective systemic therapies, generally fewer than 5% of patients with adenocarcinoma of the pancreas survive 5 years after diagnosis.
  • The median survival in metastatic pancreatic cancer is nearly six months.Today, surgery remains the only curative therapeutic option, and the standard treatment in patients with advanced disease is gemcitabine.
  • New strategies for resectable and unresectable pancreatic cancer are under active investigation,such as neoadjuvant or adjuvant chemoradiotherapy or combinations of gemcitabine with new cytotoxic agents (oxaliplatin, cetuximab, gefitinib, bevacizumab) with promising results.
  • In patients with locally advanced pancreatic cancer and good performance status, chemoradiotherapy should be considered.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351494.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 37
  •  go-up   go-down


6. Barreda Bolaños F, Landeo Aliaga I, Pando Huarcaya S, Bayro Peñaloza F: [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography]. Rev Gastroenterol Peru; 2008 Apr-Jun;28(2):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic adenocarcinoma in young patient diagnosed by endoscopic ultrasonography].
  • [Transliterated title] Adenocarcinoma de páncreas en paciente joven diagnosticado por ultrasonografía endoscópica.
  • The Pancreatic adenocarcinoma appears generally in patients with more than 60 years old.
  • The tomografic image showed a mass located in the head of the pancreas with hepatic and ganglionar metastases.
  • It was evaluated by means of endoscopic ultrasonography (USE) and performed a directed fine needle puncture aspiration (PAAF), that obtained a bad differentiated adenocarcinoma from the pancreas.
  • We present the case by the unusual occurrence in the related age group and by the importance of the puncture guided by endoscopic ultrasonography in the diagnosis and handling of this pathology [corrected]
  • [MeSH-major] Adenocarcinoma / ultrasonography. Endosonography. Pancreatic Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Gastroenterol Peru. 2008 Jul-Sep;28(3):293
  • (PMID = 18641779.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


7. Badía Bartolomé C, Díaz Formoso FJ, Rodríguez Falcón R, Marchena Gómez J: [Groove pancreatitis and its differential diagnosis with pancreatic adenocarcinoma]. Gastroenterol Hepatol; 2009 Jan;32(1):22-8
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Groove pancreatitis and its differential diagnosis with pancreatic adenocarcinoma].
  • [Transliterated title] Pancreatitis del surco y su diagnóstico diferencial con el adenocarcinoma de páncreas.
  • We analyzed the clinical, radiographic and histologic characteristics, as well as the difficulties that arose in the differential diagnosis between groove pancreatitis (a benign entity consisting of a segmental form of chronic pancreatitis occurring as a sheet-like scar in the area of pancreatoduodenal groove) and adenocarcinoma of the pancreas.
  • To this end, four cases with abnormalities in the groove area were retrospectively reviewed, three with groove pancreatitis, and one with adenocarcinoma of the pancreas.
  • The important role of imaging techniques is highlighted, with emphasis on magnetic resonance imaging of the pancreas and magnetic resonance cholangiography, which reveal certain differentiating characteristics between these two entities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Duodenitis / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Cholangiopancreatography, Endoscopic Retrograde. Cholangiopancreatography, Magnetic Resonance. Cholelithiasis / complications. Cholelithiasis / diagnosis. Chronic Disease. Diagnosis, Differential. Duodenum / pathology. Fatal Outcome. Humans. Intestinal Mucosa / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Pancreaticoduodenectomy. Pancreatitis, Alcoholic / complications. Retrospective Studies

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterol Hepatol. 2009 Nov;32(9):662-3 [19525034.001]
  • (PMID = 19174095.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Muroni M, D'Angelo F, Pezzatini M, Sebastiani S, Noto S, Pilozzi E, Ramacciato G: Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int; 2010 Feb;9(1):97-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous gastric adenocarcinoma and pancreatic ductal adenocarcinoma.
  • BACKGROUND: The association between gastric and pancreatic carcinoma is a relatively rare condition.
  • Gastric cancer associated with pancreatic cancer is uncommon.
  • Computed tomography and magnetic resonance showed a gastric thickening in the antral and pyloric portion and a nodular mass (3 X 1.7 cm) in the uncinate portion of the pancreas.
  • Histological examination of the specimen demonstrated a moderately differentiated adenocarcinoma of the stomach and a poorly differentiated ductal adenocarcinoma of the pancreas.
  • CONCLUSIONS: Long survival is rare in patients with associated gastric and pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133238.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Wong JC, Lu DS: Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol; 2008 Dec;6(12):1301-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging of pancreatic adenocarcinoma by imaging studies.
  • Imaging studies play a crucial role in the diagnosis and management of patients with pancreatic adenocarcinoma.
  • Computed tomography (CT) is the most widely available and best-validated modality for imaging patients with pancreatic adenocarcinoma.
  • To maximize the diagnostic efficacy of CT, use of a pancreas protocol is mandatory.
  • The sensitivity of CT for diagnosis of pancreatic adenocarcinoma (89%-97%) and its positive predictive value for predicting unresectability (89%-100%) are high.
  • Magnetic resonance imaging has not been shown to perform better than CT for the diagnosis and staging of pancreatic adenocarcinoma, but can be helpful as an adjunct to CT, particularly for evaluation of small hepatic lesions that cannot be fully characterized by CT.
  • Ultrasound is often the first study obtained in patients with obstructive jaundice or unexplained abdominal pain, but its utility for diagnosis and staging of patients with pancreatic adenocarcinoma is limited.
  • Positron emission tomography/CT combines the functional information provided by positron emission tomography with the anatomic information provided by CT and is a promising modality for imaging of patients with pancreatic adenocarcinoma, but its utility has not been established.
  • Endoscopic ultrasound is generally considered superior to CT for the diagnosis and local staging of pancreatic cancer, but is limited by availability and inability to assess for distant metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Pancreas / radiography. Pancreas / ultrasonography. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948228.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


10. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W, Campbell F, Brentnall TA, Costello E, Neoptolemos J, Lemoine NR: Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology; 2005 Nov;129(5):1454-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.
  • BACKGROUND & AIMS: Markers to differentiate among pancreatic adenocarcinoma, chronic pancreatitis, and normal pancreas would be of significant clinical utility.
  • This study was therefore designed to analyze the proteome of such specimens and identify new candidate proteins for differential diagnosis.
  • METHODS: A PowerBlot analysis with more than 900 well-characterized antibodies was performed with tissue specimens from patients with chronic pancreatitis, pancreatic adenocarcinoma, and normal pancreas.
  • RESULTS: A total of 30 and 102 proteins showed significant deregulation between normal pancreas when compared with chronic pancreatitis and pancreatic adenocarcinoma, respectively, and although a substantial proportion were found similarly dysregulated in both chronic pancreatitis and pancreatic adenocarcinoma, several proteins were identified as potential disease-specific markers.
  • CONCLUSIONS: A large number of proteins are differentially expressed in chronic pancreatitis and pancreatic adenocarcinoma compared with normal pancreas.
  • [MeSH-major] Adenocarcinoma / physiopathology. Pancreatic Neoplasms / physiopathology. Pancreatitis, Chronic / physiopathology. Protein Array Analysis. Proteomics

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285947.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Miller FH, Rini NJ, Keppke AL: MRI of adenocarcinoma of the pancreas. AJR Am J Roentgenol; 2006 Oct;187(4):W365-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI of adenocarcinoma of the pancreas.
  • OBJECTIVE: CT is the established imaging technique for evaluation of pancreatic adenocarcinoma.
  • The objective of this study is to illustrate the strengths of MRI for evaluating pancreatic adenocarcinoma.
  • CONCLUSION: The superior soft-tissue contrast of MRI compared with CT is useful in the detection and characterization of non-contour-deforming pancreatic masses.
  • [MeSH-major] Adenocarcinoma / diagnosis. Magnetic Resonance Imaging. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / radiography. Diagnosis, Differential. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Pancreatitis / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985107.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Sahani DV, Shah ZK, Catalano OA, Boland GW, Brugge WR: Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol; 2008 Jan;23(1):23-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiology of pancreatic adenocarcinoma: current status of imaging.
  • Pancreatic adenocarcinoma is one of the leading causes of cancer death in the West, with a poor overall 5-year survival rate of only 4%.
  • Tumor serum marker CA 19-9 is sensitive, although not specific for the diagnosis of adenocarcinomas of the pancreas.
  • Many modalities are available to image the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18171340.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 66
  •  go-up   go-down


13. Wisnoski NC, Townsend CM Jr, Nealon WH, Freeman JL, Riall TS: 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery; 2008 Aug;144(2):141-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma.
  • BACKGROUND: Acinar cell carcinoma (ACC) is a rare cancer of the pancreas accounting for approximately 1% of nonendocrine tumors.
  • OBJECTIVE: Our goal was to evaluate a large population-based cohort of patients with ACC and compare their demographic factors and outcomes to those of patients with pancreatic adenocarcinoma (PA).
  • The mean age at the time of diagnosis was significantly lower for ACC than PA (56 years vs 70 years, P < .001).
  • Multivariate Cox proportional hazards regression model results suggested patients with ACC were less likely to die (hazard ratio = 0.241; 95% confidence interval, 0.22-0.27) than patients with PA after controlling for gender, race, stage, SEER region of diagnosis, and surgical resection status.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Acinar Cell / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656619.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Brown D, Boyd A, Henrickson C, Hampton J, Almani F, Ben-Josef E, Zalupski M, Simeone D, Taylor J, Armitage R, Riba M: Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas. J Clin Oncol; 2009 May 20;27(15_suppl):e15678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of depression, sleep-related disturbances, and anxiety and their effect on quality of life in patients with adenocarcinoma of the pancreas.
  • : e15678 Purpose: To evaluate the prevalence of depression, sleep related disturbances and anxiety and their effect on quality of life in patients with recently diagnosed adenocarcinoma of the pancreas who present to a multidisciplinary pancreatic cancer clinic.
  • A minority (2 pts, 8%) had PSWQ scores characteristic of an anxiety disorder, while 33% (8 pts) had moderate anxiety scores.
  • CONCLUSIONS: Our results indicate that mild to moderate depressive symptoms, anxiety and potential sleep problems are common in patients referred to a multidisciplinary pancreatic cancer clinic.
  • To better characterize the relationship of depression (and potential causes) with pancreatic cancer, additional prospective longitudinal studies are needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ho AS, Huang X, Cao H, Koong AC, Le QT: Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):4624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients.
  • Moreover, since pancreatic adenocarcinomas have been previously shown to be extremely hypoxic, we hypothesized that miR-210 may be elevated in the plasma of these patients compared to non-cancer controls.
  • Here, we compared the circulating plasma levels of miR-210 in pancreatic cancer patients and controls using a novel miRNA extraction approach and quantitative PCR.
  • METHODS: Pretreatment EDTA plasma samples were obtained from pancreatic cancer patients and age-matched non-cancer controls. miRNA was extracted from 40ul of plasma and reverse transcribed to cDNA.
  • The procedure was performed on the initial 11 pairs of age-matched pancreatic cancer patients and non- cancer controls, then validated with a second cohort of 12 pancreatic cancer patients and 11 controls.
  • There is a statistically significant four-fold increase of mir-210 expression in pancreatic cancer patients compared to normal controls (Student's t-test, p <0.0001).
  • Its expression is significantly higher in the blood of pancreatic cancer patients compared to controls and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964211.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Reni M, Cereda S, Aprile G, Tronconi MC, Milandri C, Passoni P, Rognone A, Balzano G, Di Carlo V, Villa E: A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of adjuvant chemotherapy with cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG regimen) or gemcitabine alone after curative resection for pancreatic cancer.
  • : 4608 Background: The PEFG regimen yielded a statistically relevant outcome advantage as compared with gemcitabine (G) in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964177.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lee J, Lee S, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S: Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA). J Clin Oncol; 2009 May 20;27(15_suppl):e15553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of neoadjuvant fixed dose rate (FDR) gemcitabine with capecitabine (GX) combination chemotherapy in locally advanced pancreatic adenocarcinoma (LAPA).
  • : e15553 Background: To determine the efficacy and safety of fixed dose rate (FDR) gemcitabine and capecitaibne (GX) combination chemotherapy for locally advanced pancreatic adenocarcinoma Methods: Patients with histologically confirmed LAPA were eligible for this prospective phase II trial.
  • Dynamic pancreas/pelvic CT, MRI and FDG-PET were undertaken to assess the resectability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962334.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Marten A, Büchler MW, Wente MN, Schmidt J: Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology. J Clin Oncol; 2009 May 20;27(15_suppl):4626

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble iC3b as an early marker for pancreatic adenocarcinoma compared to CA 19.9 and radiology.
  • : 4626 Background: Pancreatic adenocarcinoma as an aggressive tumor still lacks specific markers.
  • Resection offers the only potential cure, and earlier diagnosis could benefit many patients.
  • Complement regulatory proteins are highly expressed on pancreatic carcinoma cells and detectable in patient's urine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964206.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Verslype C, Vervenne W, Bennouna J, Humblet Y, Cosaert J, Van Cutsem E: Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. J Clin Oncol; 2009 May 20;27(15_suppl):4532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study.
  • : 4532 Background: The EGFR inhibitor, erlotinib (E), in combination with gemcitabine (G), provides a significant survival benefit in metastatic pancreatic cancer.
  • METHODS: Chemo-naïve patients (pts) with metastatic pancreatic adenocarcinoma and KPS of 60-100 were randomized to GE-placebo (GE-P) or GE-B; pts received B/P 5mg/kg q2w plus E (100mg/d) and G (1,000mg/m<sup><sup>2</sup></sup>) given weekly for 7 weeks during the first 8-weekly cycle, followed by weekly for 3 weeks during subsequent 4-weekly cycles.
  • JCO 2007), in pts with advanced pancreatic cancer.
  • Studies are under way to prospectively investigate the relationship between rash and efficacy with erlotinib-based regimens in pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Cohen DJ, Ryan T, Moskovits T, Cazeau N, Newman E, Pachter HL, Hochster HS: Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and tolerability of combined gemcitabine (G) and erlotinib (E) plus sorafenib (S) in the first-line treatment of metastatic pancreatic cancer.
  • : e15594 Background: The addition of E to G results in improved survival for patients(pts) with locally advanced and metastatic pancreatic cancer.
  • Many pancreatic tumors have constitutively activated ras/raf pathways and overexpress VEGF.
  • Sorafenib, a multitargeted tyrosine kinase inhibitor which targets VEGR 1-3, PDGFR-α and β and the RAF/MEK/ERK pathway, when combined with G and E may synergize with these agents resulting in a more complete blockade of the signal transduction cascade in pancreatic cancer growth and progression and therefore improve outcome.
  • METHODS: Pts with previously untreated, histologically confirmed, unresectable pancreatic adenocarcinoma, ECOG PS 0-1, and adequate organ function were eligible and received G 1,000 mg/m<sup>2</sup> over 30 min weekly × 3 every 4 weeks.
  • CONCLUSIONS: The combination of G and E plus S in the treatment of advanced pancreatic cancer is a well tolerated regimen without significant increased toxicity as compared to gemcitabine alone, except for very manageable cutaneous reactions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962883.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hwang JY, Yoo C, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S, Lee J: A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):4618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy.
  • : 4618 Background: Only few clinical trials have been conducted in patients with advanced pancreatic cancer after failure of first-line gemcitabine-based chemotherapy.
  • We conducted a randomized phase II trial of modified FOLFOX vs. modified FOLFIRI.3 as second-line regimen for the patients with gemcitabine refractory pancreatic cancer ( NCT00786006 ).
  • METHODS: Patients with advanced pancreatic adenocarcinoma previously treated with gemcitabine were randomly assigned to FOLFOX or FOLFIRI.3 stratifying by age (≤ 65 vs. >65), performance status (0-1 vs. 2) and prior response to gemcitabine (PR/SD vs. PD).
  • CONCLUSIONS: Both FOLFOX and FOLFIRI.3 were tolerated with manageable toxicity, offering modest activity as second-line treatment of patients with advanced or metastatic pancreatic cancer, previously treated with gemcitabine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Maréchal R, Demetter P, Berton A, Salmon I, Van Laethem J: Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CXCR4 expression in resected pancreatic adenocarcinoma (PA) with relapse and survival after adjuvant radiochemotherapy (RCT).
  • This chemoreceptor could be implicated in the resistance of pancreatic cancer cells to RCT and its targeted inhibition deserves clinical evaluation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963130.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Oh D, Lee K, Lee K, Sohn C, Park Y, Zang D, Ryoo H, Bang Y: A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research. J Clin Oncol; 2009 May 20;27(15_suppl):4607

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: Combined analysis with translational research.
  • : 4607 Background: To confirm the efficacy and toxicity of erlotinib (E) in combination with gemcitabine (G) and capecitabine (C) when used as a first-line therapy in patients (pts) with metastatic/recurrent pancreatic cancer Methods: Pts with advanced pancreatic adenocarcinoma, with measurable lesion were eligible for the study.
  • Locally advanced pancreatic cancer was excluded.
  • CONCLUSIONS: Erlotinib in combination with gemcitabine and capecitabine showed promising efficacy and good tolerability in metastatic pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964140.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, Korn R, Desai N, Iglesias J, Hidalgo M: SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. J Clin Oncol; 2009 May 20;27(15_suppl):4525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study.
  • : 4525 Background: Pancreatic cancer cells and surrounding stroma are known to overexpress SPARC (secreted protein acid rich in cysteine), which is associated with poor clinical outcomes. nab-P, an albumin-bound nanoparticle form of paclitaxel increased tumor accumulation of paclitaxel through binding of albumin to SPARC.
  • METHODS: nab-P doses (100-150 mg/m<sup>2</sup>) + (G) (1000 mg/m<sup>2</sup>) were given on days 1, 8, and 15 of a 28-day cycle to pts with metastatic pancreatic adenocarcinoma and with no prior chemotherapy for their metastatic disease.
  • CONCLUSIONS: The combination of nab-P and G was generally well tolerated and had substantial enough antitumor activity in patients with pancreatic cancer to warrant a phase III clinical trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962720.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Thieltges S, Kalinina T, Krohn A, Simon R, Moeller-Krull M, Dierlamm J, Izbicki J, Yekebas E: Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods. J Clin Oncol; 2009 May 20;27(15_suppl):e15609

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of chromosomal regions that harbor novel genes important for pancreatic cancer pathogenesis by genome-wide screening methods.
  • : e15609 Background: Pancreatic adenocarcinoma is a genetically highly complex and heterogenous tumor type with strong genetic instability which makes it resistant to therapy.
  • METHODS: We report the use of an Affymetrix Genome-Wide Human single nucleotide polymorphism (SNP) Array 6.0 (906,600 SNPs) to screen for gene copy number changes and allelic imbalances in 8 microdissected primary pancreatic tumors and 7 established pancreatic cancer cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962682.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Ishii H, Furuse J, Boku N, Okusaka T, Ikeda M, Ohkawa S, Fukutomi A, Hamamoto Y, Nakamura K, Fukuda H: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506. J Clin Oncol; 2009 May 20;27(15_suppl):e15578

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG 0506.
  • : e15578 Background: Fluorouracil (5-FU) chemoradiotherapy has been accepted as standard care for locally advanced pancreatic cancer (LAPC); however, it has not been shown to be superior to chemotherapy alone in gemcitabine (Gem) era.
  • METHODS: Eligibility criteria included the following: patients (pts) with histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma, pts with UICC clinical stage III (T4N0-1 and M0), all lesions are assumed to be included in the radiation field of 15 cm square, age 20 or older, no prior treatment for LAPC, ECOG performance status of 0, 1 or 2, and adequate organ function.
  • Patient characteristics were: median age; 67.5 (45-80), male/female; 35/15, PS 0/1/2; 30/20/0, pancreatic head/body-tail; 26/24.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962370.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, Baselga J, Piera A, Pardos I, Rye R, Smyth JF: Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):2568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No objective responses were seen but 3 pts with pancreatic adenocarcinoma, hepatocarcinoma and lower esophagus adenocarcinoma presented stable disease lasting >3 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Carr BI, Summers D, Menefee L, Pierpoint S, Yeo C, Kennedy E, Lavu H: Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e20692

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and pain assessment in 36 patients with resected pancreas adenocarcinoma: Preliminary analysis.
  • : e20692 Background: In order to begin to understand the effects of disease on the patient (pt) and possibly of the pt on the disease, we have begun a systematic psychological inventory of all our pts who have has a pancreatectomy for pancreas adenocarcinoma and have began to correlate this with disease extent, and later with survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961756.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Sams VG, Akin HE: Umbilical Hernia Repair in Patient with Ascites with Incidental Finding of Pancreatic Adenocarcinoma Metastasis in Hernia Sac. Am Surg; 2010 Aug 01;76(8):144-145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical Hernia Repair in Patient with Ascites with Incidental Finding of Pancreatic Adenocarcinoma Metastasis in Hernia Sac.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28958238.001).
  • [ISSN] 1555-9823
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA: Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15677

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma.
  • : e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis.
  • The combination of gemcitabine with concurrent radiation therapy is a promising approach that is being investigated in patients' unresectable pancreatic cancer.
  • AIM OF THE WORK: The efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate for patients locally advanced, non metastatic pancreatic cancer was assessed.
  • CONCLUSIONS: preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non metastatic pancreatic cancer by increasing the resectability without significant acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962829.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bonnetain F, Maillard E, Seitz J, Mitry E, Ychou M, Gasmi M, Raoul J, Mariette C, Bedenne L, Dahan L: Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). J Clin Oncol; 2009 May 20;27(15_suppl):e17544

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal analysis of quality of life (QoL) within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963761.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Dahan L, Methy N, Seitz J, Mitry E, Ychou M, Gasmi M, Raoul J, Mariette C, Bedenne L, Bonnetain F: Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA). J Clin Oncol; 2009 May 20;27(15_suppl):e15583

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of first-line and second-line PFS definitions within a randomized phase III trial in patients (pts) with metastatic pancreatic adenocarcinoma (MPA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962358.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Prowda J, Schreibman S, Levitz J: Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4623

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.
  • This GTX regimen was designed to inhibit MEK-ERK phosphorylation and increase BAX and BAK and also decrease BCL-2 in pancreatic cancer cell lines.
  • Based on these findings, we pursued a prospective clinical trial evaluating the activity of GTX in previously untreated patients with metastatic pancreatic cancer.
  • METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.
  • CONCLUSIONS: The combination of gemcitabine, docetaxel, and capecitabine has activity in metastatic pancreatic cancer with a median survival over 1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Viret F, Ychou M, Baey C, Bennouna J, Adenis A, Peiffert D, Mornex F, Celier P, Montoto-Grillot C, Ducreux M: A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial. J Clin Oncol; 2009 May 20;27(15_suppl):4625

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of radiation and docetaxel and cisplatin in the treatment of locally advanced pancreatic carcinoma. FNCLCC-ACCORD 09 /0201 trial.
  • : 4625 Background: Locally advanced pancreatic carcinoma remains a challenging tumor with no clear standard of care in terms of radio-chemotherapy.
  • The purpose of this phase II trial was to determine the efficacy and the toxicity of radiotherapy and docetaxel and cisplatin in histologically proven adenocarcinoma of the pancreas.
  • RESULTS: 51 pts (20 women and 31 men, with median age of 62 years) with disease considered to be unresectable but confined to pancreas area and celiac nodes were included between 06/10/2003 and 15/02/2008.
  • 6 pts underwent secondary pancreatic resection (4 compete resection and 1 pt with histological complete remission).
  • CONCLUSIONS: The association docetaxel+cisplatin+radiotherapy has limited effect in patients with locally advanced pancreatic carcinoma but major objective responses have been observed allowing secondary resections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Cereda S, Rognone A, Ghidini M, Rezzonico S, Passoni P, Mazza E, Nicoletti R, Zerbi A, Villa E, Reni M: A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel. J Clin Oncol; 2009 May 20;27(15_suppl):4614

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of two different four-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel.
  • : 4614 Background: The combination of cisplatin (P), epirubicin (E), 5-fluorouracil (F) and gemcitabine (G) (PEFG regimen) yielded a progression-free survival at 6 months from treatment start (PFS6) of about 50% and a 1-year overall survival (OS) around 40% in patients with advanced pancreatic adenocarcinoma (PA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Mazzer M, Zanon E, Foltran L, De Pauli F, Cardellino G, Iaiza E, Ermacora P, Aprile G, Fasola G: Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15597

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line pemetrexed-oxaliplatin combination for advanced pancreatic adenocarcinoma.
  • : e15597 Background: Few regimens showed efficacy in advanced pancreatic cancer patients (pts) who had failed a first-line gemcitabine-based therapy.
  • METHODS: Pancreatic cancer pts with advanced disease, PS>60, age>18 years, who progressed after a gemcitabine-based therapy were enrolled in a phase II trial, and treated with pemetrexed 500 mg/mq followed by oxaliplatin 120 mg/mq, day 1 every 3 weeks, together with adequate oral folinic acid and intramuscular vitamin B12 supplementation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Smith CD, Maines LW, Zhuang Y, Green CL, Keller SN, Beljanski V, Knaak C, Wang W: Preclinical development of orally available sphingosine kinase inhibitors. J Clin Oncol; 2009 May 20;27(15_suppl):e14615

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor activity was assessed in an allogeneic model utilizing murine JC mammary adenocarcinoma cells growing in Balb/c mice, and a xenograft model of human Bxpc pancreatic adenocarcinoma cells growing in scid-mice.
  • CONCLUSIONS: These newly developed SK inhibitors provide orally-available drug candidates for the treatment of pancreatic cancer and other diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964127.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Ueno H, Okusaka T, Furuse J, Ishii H, Saijo N, Saito Y, Sawada J, Sakamoto H, Yoshida T, Sato Y: Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):4611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a genome-wide association study to detect candidate polymorphisms associated with overall survival in stage IV pancreatic adenocarcinoma patients receiving gemcitabine monotherapy.
  • We performed a genome-wide association study (GWAS) in Japanese patients with stage IV pancreatic adenocarcinoma receiving gemcitabine (Gem) monotherapy.
  • METHODS: Metastatic pancreatic ductal adenocarcinoma patients who had previously received neither radiation nor chemotherapy were eligible in this study.
  • CONCLUSIONS: GWAS is a powerful tool to search for new prognostic biomarkers for patients with stage IV pancreatic adenocarcinoma receiving Gem monotherapy and may reveal as yet unexplored molecular pathways which correlate with drug response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964191.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Uronis HE, Bullock K, Blobe G, Hsu S, Morse M, Nixon A, Haley S, O'Neill M, Hurwitz H, Bendell J: A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 25 pts have been enrolled, including 21 with pancreatic adenocarcinoma, 3 of whom had received prior G. 21 pts were evaluable for toxicity and 18 for efficacy.
  • To address these toxicities, once daily dosing of D will be explored, followed by an expanded cohort of G + daily D vs G + bid D in pts with treatment-naïve pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Ben-Josef E, Griffith K, Francis IR, Khan G, Lawrence TS, Abrams R, Leslie W, Zalupski M: Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4602

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer.
  • : 4602 Background: Current treatments of non-metastatic, unresectable pancreatic cancer result in poor survival and nearly uniform local persistence of disease.
  • METHODS: Eligibility included tissue diagnosis of adenocarcinoma, unresectable by radiological criteria, Zubrod performance of 0-2, ANC of ≥ 1500/mm3, platelets ≥ 100,000/mm3, creatinine < 2 mg/dl, bilirubin < 3 mg/dl, ALT and AST ≤ 2.5 x ULN, and informed consent.
  • GTV was defined on pancreas protocol CT in the treatment position.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964152.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Moore MJ, Tang P, Renouf D, Major P, Hedley D, Paterson V, Wang L, Dhesy-Thind B, Southwood B, Doyle L: A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15634

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer.
  • Preclinical studies suggest that Eribulin may be effective in pancreatic cancer.
  • The primary objective of this study was to determine the objective response rate (complete and partial) to Eribulin in patients with advanced, pancreatic adenocarcinoma that had progressed after gemcitabine based therapy.
  • METHODS: Eligibility criteria included histologically confirmed pancreatic adenocarcinoma; measurable locally advanced, or metastatic disease; disease progression after gemcitabine; and ECOG performance status 0-2.
  • CONCLUSIONS: Eribulin was well tolerated and did not result in any objective responses in refractory pancreatic cancer.
  • Further studies of eribulin in pancreatic cancer may be warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962741.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Ioka T, Takakura R, Nakaizumi A, Tanaka S, Iishi H, Nakamura S, Nishiyama K, Oohigashi H, Ishikawa O, Watanabe A, Mukai S: A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter randomized phase II study of full-dose gemcitabine and concurrent radiotherapy comparing gemcitabine alone for the unresectable locally advanced pancreatic adenocarcinoma.
  • : e15512 Background: Some of locally advanced pancreatic cancers (LAPC) are considered to include a potential micro metastasis.
  • METHODS: Patients with histologically or cytologically proven pancreatic adenocarcinoma were eligible for this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962283.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F: Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol; 2008 Jan;129(1):81-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.
  • Even though the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on fine-needle aspiration biopsy (FNAB) specimens have been well defined, a diagnostic challenge is still present.
  • We immunohistochemically evaluated the diagnostic value of S100P on cell-block and/or smear preparations in 58 cases of FNAB specimens of the pancreas.
  • The 58 cases were divided into 4 groups: 1, 32 cases of PDA; 2, 6 cases with an atypical or "suspicious" diagnosis; 3, 14 cases of benign or reactive ductal epithelium; and 4, 6 cases of endocrine tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / diagnosis. Carrier Proteins / metabolism. Nuclear Proteins / metabolism. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Islet Cell / diagnosis. Adenoma, Islet Cell / metabolism. Biopsy, Fine-Needle. Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / metabolism. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Islets of Langerhans / metabolism. Islets of Langerhans / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089492.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / S100PBP protein, human
  •  go-up   go-down


45. Sheibani-Rad S, Velanovich V: Effects of depression on the survival of pancreatic adenocarcinoma. Pancreas; 2006 Jan;32(1):58-61
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of depression on the survival of pancreatic adenocarcinoma.
  • OBJECTIVES: Depression frequently predates the diagnosis of pancreatic adenocarcinoma.
  • The purpose of this study was to assess whether survival after resection for pancreatic cancer is shortened by the pretreatment presence of depression.
  • METHODS: A database of all patients diagnosed with pancreatic cancer was retrospectively reviewed for depression, resection, and chemotherapy and/or radiation therapy.
  • RESULTS: The median survival time for all depressed patients with pancreatic cancer was 5 months compared with 4 months for all nondepressed patients with pancreatic cancer (P < 0.9).
  • Depression, although common among patients with pancreatic cancer, does not affect survival.
  • [MeSH-major] Adenocarcinoma / psychology. Depression / epidemiology. Pancreatic Neoplasms / psychology

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16340745.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Takamori H, Kanemitsu K, Tsuji T, Kusano S, Chikamoto A, Okuma T, Iyama K: Metastatic gastric tumor secondary to pancreatic adenocarcinoma. J Gastroenterol; 2005 Feb;40(2):209-12
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic gastric tumor secondary to pancreatic adenocarcinoma.
  • Metastatic disease, from the pancreas, involving the stomach is an unusual clinical event.
  • Local recurrence, liver metastases, and peritoneal spread are the most common recurrent patterns after curative resection of pancreatic cancer.
  • We report a patient who suffered from gastric metastasis secondary to pancreatic adenocarcinoma 1 year after pancreatectomy.
  • A 49-year-old woman underwent distal pancreatectomy with intraoperative radiation therapy for cancer of the body of the pancreas in October 2002.
  • The histological diagnosis was well-differentiated adenocarcinoma of the pancreas, stage IIB; T1N1M0.
  • Histological diagnosis of the biopsy specimen was well-differentiated adenocarcinoma, and immunohistochemical studies, using anti-cytokeratin 7 and -20 monoclonal antibodies, were compatible with gastric metastasis from pancreatic carcinoma.
  • Histopatholoical examination of the resected specimen revealed submucosal growth of the metastatic cancer (well-differentiated adenocarcinoma).
  • [MeSH-major] Adenocarcinoma / secondary. Pancreatic Neoplasms / pathology. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770407.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


47. Guo JH, Wang WJ, Liao P, Zhang CY, Jin DY, Lou WH, Zhang SC: [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):33-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of serum protein profiling in diagnosis, prognosis and evaluation of curative effect of pancreatic adenocarcinoma].
  • OBJECTIVE: To establish decision tree and logistic regression classification models for diagnosing pancreatic adenocarcinoma (PaCa) and for screening serum biomarkers related to evaluation of different stages and curative effects.
  • METHODS: Serum samples obtained from subjects with pancreatic adenocarcinoma (n = 58) and normal pancreas (n = 51) were applied to strong anion exchange chromatography (SAX2) chips for protein profiling by SELDI-TOF-MS to screen multiple serum biomarkers.
  • RESULTS: Average of 61 mass peaks were detected at the molecular range of 2000-30,000, ten decision trees with the highest cross validation rate were chosen to construct the classification models, which can differentiate PaCa from normal pancreas with a sensitivity of 83.3% and a specificity of 100%.
  • CONCLUSION: Decision tree and logistic regression classification models of the mass peaks screened by SELDI-TOF-MS serum profiling can be used to differentiate pancreatic adenocarcinoma from normal pancreas, and is superior to CA 199.
  • The detected mass peaks are helpful for the evaluation of curative effect and prognosis of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Blood Proteins / analysis. Pancreatic Neoplasms / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20211064.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


48. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB: Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg; 2008 Mar;247(3):456-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
  • OBJECTIVE: To determine long-term survival after pancreatoduodenectomy for pancreatic ductal adenocarcinoma and to identify clinical factors associated with long-term survival.
  • SUMMARY BACKGROUND DATA: The prognosis for long-term survival even after potentially curative resection for pancreatic adenocarcinoma is thought to be poor.
  • Clinical factors determining short-term survival after pancreatic resection are well studied, but prognostic factors predicting long-term survival with a potential for cure are poorly understood.
  • METHODS: A case-control study was conducted of 357 patients who underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma between 1981 and 2001.
  • Histologic specimens were reanalyzed to confirm diagnosis.
  • Five-year survival was no guarantee of cure because 16% of this subset died of pancreatic cancer up to 7.8 years after operation.
  • CONCLUSION: Pancreatoduodenectomy for adenocarcinoma in the head of pancreas can provide long-term survival in a subset of patients, particularly in the absence of lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376190.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Serum Albumin
  •  go-up   go-down


49. Agarwal B, Ludwig OJ, Collins BT, Cortese C: Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma. Clin Gastroenterol Hepatol; 2008 Dec;6(12):1425-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunostaining as an adjunct to cytology for diagnosis of pancreatic adenocarcinoma.
  • BACKGROUND & AIMS: Serial analysis of gene expression has helped identify several proteins that are expressed differentially in pancreatic cancer and are highly sensitive and specific for pancreatic adenocarcinoma.
  • We evaluated if the diagnostic accuracy of pancreatic cancer from endoscopic ultrasound (EUS)-fine-needle aspiration (FNA) can be improved by combined evaluation of cytology and immunostaining with these markers.
  • RESULTS: In resection specimens, the majority of pancreatic adenocarcinomas expressed all 5 markers but fascin, maspin, and carcinoembryonic antigen-related cell adhesion molecule 6 also were expressed abnormally in normal pancreata and in chronic pancreatitis.
  • It was feasible and useful to perform immunostaining in cell blocks and direct smear for diagnosing pancreatic cancer.
  • In cases requiring a second cytologic consultation, a combined evaluation of cytologic morphology and immunostaining had 90% accuracy for a pancreatic adenocarcinoma diagnosis.
  • CONCLUSIONS: In conclusion, immunostaining with newer protein markers is feasible in EUS-FNA specimens and can assist cytopathologists in diagnosing pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cell Biology. Pancreatic Neoplasms / diagnosis. Staining and Labeling / methods
  • [MeSH-minor] 14-3-3 Proteins / analysis. Biopsy. GPI-Linked Proteins. Humans. Membrane Glycoproteins / analysis. Pancreas / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081530.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


50. Jarry J, Belleannee G, Rault A, Sa Cunha A, Collet D: Can an intraductal papillary mucinous tumor be a potential indicator of concurrent adenocarcinoma of the pancreas? JOP; 2010;11(1):55-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can an intraductal papillary mucinous tumor be a potential indicator of concurrent adenocarcinoma of the pancreas?
  • CONTEXT: Despite the recent progress of diagnostic and therapeutic modalities, survival rates of pancreatic adenocarcinoma remain poor, mainly due to late diagnosis.
  • CASE REPORT: We report the case of a 56-year-old man who was diagnosed with a symptomatic intraductal papillary mucinous tumor of the pancreas located in the uncus.
  • This tumor was associated with a concurrent stenosis of the isthmic pancreatic duct which resulted in a distal dilation.
  • During the procedure, a concomitant adenocarcinoma was diagnosed 2 cm from the primary intraductal papillary mucinous tumor, causing the isthmic stenosis.
  • A second resection was then performed to the left of the pancreatic isthmus, and adjuvant chemotherapy was performed.
  • CONCLUSION: We discuss the possibility that intraductal papillary mucinous tumors may be a "red flag" enabling earlier diagnosis of a concurrent pancreatic adenocarcinoma arising in another area of the pancreas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Early Detection of Cancer. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065554.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


51. Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H, Fujita H, Nakata K, Tanaka M: MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol; 2010 Dec;17(12):3120-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma.
  • BACKGROUND: Detection of aberrant microRNA (miR) expression may contribute to diagnosis and prognosis of various cancers.
  • The aim of this study is to evaluate the correlation between miR-203 expression and prognosis of patients with pancreatic adenocarcinoma after curative resection.
  • METHODS: A total of 113 formalin-fixed paraffin-embedded tissue samples of pancreatic adenocarcinoma, 20 samples of chronic pancreatitis, and 8 samples of normal pancreas were obtained.
  • RESULTS: miR-203 was overexpressed in pancreatic adenocarcinoma samples compared with chronic pancreatitis (P < 0.001) and normal pancreas (P = 0.001) samples.
  • An association between miR-203 expression and clinicopathological factors of pancreatic adenocarcinoma was not observed.
  • CONCLUSIONS: miR-203 expression is a new prognostic marker in pancreatic adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. MicroRNAs / genetics. Pancreatic Neoplasms / genetics. Pancreatitis, Chronic / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / metabolism. Pancreas / pathology. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20652642.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN203 microRNA, human; 0 / MicroRNAs; 0 / RNA, Messenger
  •  go-up   go-down


52. Lin YH, Chen CY, Chen CP, Kuo TY, Chang FY, Lee SD: Hematemesis as the initial complication of pancreatic adenocarcinoma directly invading the duodenum: a case report. World J Gastroenterol; 2005 Feb 7;11(5):767-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematemesis as the initial complication of pancreatic adenocarcinoma directly invading the duodenum: a case report.
  • Pancreatic carcinoma is a debilitating disease and carries a poor prognosis.
  • It is a rare cause of upper gastrointestinal bleeding, even though pancreas, stomach, duodenum and jejunum are adjacent organs.
  • The incidence of pancreatic adenocarcinoma directly invading the gastrointestinal tract leading to gastrointestinal hemorrhage is very low, and most of them present with melena and hematochezia.
  • Here, we describe one unique case manifesting characteristically severe and unremitting hematemesis as an initial presentation of pancreatic adenocarcinoma.
  • Our MEDLINE search has confirmed that this is the first reported case with an initial manifestation of hematemesis from pancreatic adenocarcinoma in Asians.
  • Pancreatic adenocarcinoma directly invading duodenum complicated by hemorrhage can be a rare cause of hematemesis, and clinicians should be reminded of it while they are making differential diagnosis.
  • [MeSH-major] Adenocarcinoma / complications. Duodenum / pathology. Hematemesis / etiology. Pancreatic Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655842.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4250759
  •  go-up   go-down


53. Baruch AC, Wang H, Staerkel GA, Evans DB, Hwang RF, Krishnamurthy S: Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma. Diagn Cytopathol; 2007 Mar;35(3):143-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma.
  • Mesothelin is a potential marker of pancreatic adenocarcinoma that was recently identified by serial analysis of gene expression.
  • We evaluated the sensitivity and specificity of mesothelin as a marker of pancreatic adenocarcinoma on destained Papanicolaou (Pap) smears and unstained cellblocks from 28 patients using a monoclonal antibody to mesothelin.
  • Focal positivity for mesothelin was noted in benign pancreatic tissue in one of 10 cases.
  • The overall sensitivity and specificity of mesothelin as a marker for pancreatic adenocarcinoma were 68% and 90%, respectively.
  • The presence of occasional mesothelin expression in benign tissue, its very focal expression in malignant tissue may limit the utility of mesothelin as a marker of pancreatic adenocarcinomas in fine-needle aspiration (FNA) specimens.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Membrane Glycoproteins / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Pancreas / pathology. Papanicolaou Test. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304533.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


54. Hijioka S, Ikari T, Kamei A, Takano K, Asahara S, Fujita N, Shimizu M, Yamamoto J, Fujita R, Sasaki K: CT and MRI findings with contrast enhancement of small pancreatic adenocarcinoma in the late phase. Hepatogastroenterology; 2007 Mar;54(74):389-92
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT and MRI findings with contrast enhancement of small pancreatic adenocarcinoma in the late phase.
  • Dynamic computed tomography and magnetic resonance imaging demonstrated a mass in the body of the pancreas, which was enhanced in the late phase of the scans by administration of a contrast medium.
  • Endoscopic retrograde pancreatography showed a stenosis of the main pancreatic duct at the body, and brushing cytology from the region revealed adenocarcinoma.
  • The tumor was a well-differentiated adenocarcinoma, measuring 15 x l0 mm.
  • Marked tumor enhancement in the late phase might be a characteristic finding suggesting an early-stage pancreatic adenocarcinoma, which should be carefully checked.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / diagnosis. Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Pancreatic Neoplasms / diagnosis. Tomography, Spiral Computed
  • [MeSH-minor] Amylases / blood. Contrast Media / administration & dosage. Female. Gadolinium DTPA. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Pancreas / pathology. Pancreatectomy. Pancreatic Ducts / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523281.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Contrast Media; EC 3.2.1.- / Amylases; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


55. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA: Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg; 2008 Dec;143(12):1166-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss.
  • HYPOTHESIS: Although the safety of pancreaticoduodenectomy has notably improved over the past several decades, the reported survival of patients with pancreatic cancer remains poor.
  • We hypothesized that, in recent years, the survival of patients with pancreatic adenocarcinoma following pancreaticoduodenectomy has substantially improved.
  • SETTING: Major academic medical and pancreatic surgery center.
  • INTERVENTIONS: Pancreaticoduodenectomy for patients with a diagnosis of pancreatic adenocarcinoma.
  • RESULTS: During the time period analyzed, 182 patients underwent pancreaticoduodenectomy to treat ductal adenocarcinoma.
  • CONCLUSIONS: The survival rate for patients undergoing pancreaticoduodenectomy to treat pancreatic cancer has substantially improved.
  • [MeSH-major] Adenocarcinoma / surgery. Blood Loss, Surgical / mortality. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2009 Jun;144(6):594; author reply 594-5 [19528398.001]
  • (PMID = 19075167.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Mazziotti S, Celona A, Gaeta M: Usefulness of heavily T2-weighted magnetic resonance imaging in the diagnosis of alveolar lung metastases from pancreas mucinous adenocarcinoma. J Thorac Imaging; 2008 Feb;23(1):44-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of heavily T2-weighted magnetic resonance imaging in the diagnosis of alveolar lung metastases from pancreas mucinous adenocarcinoma.
  • We report the case of a patient with pancreatic adenocarcinoma and mucinous air-space metastases, in which the diagnosis was suspected at magnetic resonance using heavily T2-weighted images obtained with magnetic resonance hydrographic sequences.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / pathology. Pulmonary Alveoli / pathology
  • [MeSH-minor] Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347520.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


57. Soman AD, Collins JM, DePetris G, Decker GA, Silva A, Moss A, Greer W, Ashman J, Callister M, Borad MJ: Isolated supraclavicular lymph node metastasis in pancreatic adenocarcinoma: a report of three cases and review of the literature. JOP; 2010;11(6):604-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated supraclavicular lymph node metastasis in pancreatic adenocarcinoma: a report of three cases and review of the literature.
  • CONTEXT: Supraclavicular lymph nodes represent a rare site of metastasis in pancreatic cancer.
  • We report three cases of pancreatic adenocarcinoma with metastases to supraclavicular lymph nodes.
  • CASE REPORT: A 51-year-old male was diagnosed with locally advanced pancreatic adenocarcinoma on computed tomography (CT) scan.
  • The patient received systemic chemotherapy for metastatic pancreatic adenocarcinoma.
  • The second patient, a 66-year-old female with pancreatic adenocarcinoma, underwent pancreaticoduodenectomy and was found to have peripancreatic lymph node involvement.
  • PET/CT scan and biopsy revealed supraclavicular lymph node metastasis from a pancreatic adenocarcinoma primary.
  • Staging evaluations revealed a pancreatic mass for which he underwent subtotal pancreatectomy and splenectomy.
  • Histopathology revealed grade 3 pancreatic adenocarcinoma.
  • Excisional biopsy of a supraclavicular lymph node showed metastatic pancreatic adenocarcinoma.
  • CONCLUSION: In patients with pancreatic adenocarcinoma, supraclavicular lymph node metastasis represents an uncommon, but clinically significant finding that can lead to changes in treatment planning.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JOP. 2011 Jan;12(1):66-7; author reply 70 [21206107.001]
  • (PMID = 21068495.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


58. Hart B, Erickson R, LeBlanc C, Hix-Hernandez S, Shabahang M: Adenocarcinoma of the distal pancreas presenting as an intrathoracic mass. Curr Surg; 2006 Sep-Oct;63(5):330-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the distal pancreas presenting as an intrathoracic mass.
  • Tumors of the pancreatic head may present with early heralding symptoms such as obstructive jaundice.
  • Pancreatic masses within the body or tail usually have delayed diagnosis secondary to the lack of any early findings, which, in turn, leads to a higher incidence of involvement of adjacent structures, such as the superior mesenteric artery, portal vein, or superior mesenteric vein.
  • The authors report a case of advanced pancreatic adenocarcinoma in which the anomalous thoracic location of the organ resulted in the tumor being resectable.
  • This case adds support to an aggressive approach to surgical resection of distal pancreatic tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971204.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Chang KJ, Parasher G, Christie C, Largent J, Anton-Culver H: Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer; 2005 Jan 15;103(2):349-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups.
  • BACKGROUND: African Americans have a higher incidence of pancreatic adenocarcinoma compared with non-Hispanic whites.
  • METHODS: The authors conducted a population-based retrospective analysis of all patients with pancreatic adenocarcinoma in both a regional and a statewide database between 1988 and 1998.
  • Their goal was to evaluate differences in incidence rates, clinical presentation, including age at diagnosis, gender, and tumor characteristics, and treatment among race/ethnic groups.
  • RESULTS: African Americans had a higher age-adjusted incidence rate of pancreatic adenocarcinoma (8.78) compared with non-Hispanic whites (5.89), Hispanics (5.09), Asians (4.75), and all race/ethnicities combined (5.82).
  • In general, males maintained a higher incidence rate of pancreatic adenocarcinoma than females across all race/ethnicities.
  • CONCLUSIONS: African Americans in California had a higher incidence rate of pancreatic adenocarcinoma, had a slightly higher risk of presenting with advanced-stage disease and with nonresectable tumors (i.e., tumors located in the body or tail of the pancreas), and underwent less surgical treatment than all other race/ethnicities.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / ethnology. Continental Population Groups / statistics & numerical data. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • [CommentIn] Cancer. 2005 Dec 1;104(11):2530-1; author reply 2531 [16240447.001]
  • (PMID = 15593353.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Gardner TB, Barth RJ, Zaki BI, Boulay BR, McGowan MM, Sutton JE, Ripple GH, Colacchio TA, Smith KD, Byock IR, Call M, Suriawinata AA, Tsapakos MJ, Mills JB, Srivastava A, Stannard M, Lisovsky M, Gordon SR, Pipas JM: Effect of initiating a multidisciplinary care clinic on access and time to treatment in patients with pancreatic adenocarcinoma. J Oncol Pract; 2010 Nov;6(6):288-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of initiating a multidisciplinary care clinic on access and time to treatment in patients with pancreatic adenocarcinoma.
  • PURPOSE: Neoadjuvant therapy for pancreatic adenocarcinoma requires referral to multiple specialists before initiating therapy.
  • We evaluated the effect of establishing a multidisciplinary clinic (MDC) for patients with newly diagnosed pancreatic adenocarcinoma on treatment access and time to therapy.
  • METHODS: Patients with newly diagnosed pancreatic adenocarcinoma diagnosed and treated at our center were included.
  • The primary outcomes were days from diagnosis to first treatment (initiation of chemotherapy or external beam radiation), days to completion of all required consultations, and number of visits needed before initiation of therapy.
  • CONCLUSION: In patients with pancreatic adenocarcinoma undergoing neoadjuvant therapy, the establishment of a multidisciplinary pancreas tumor clinic led to improved patient access to consultations and shorter time to initial treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):995-1004 [16252135.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2117-27 [14645640.001]
  • [Cites] J Am Coll Surg. 2008 Mar;206(3):451-7 [18308215.001]
  • [Cites] Minerva Gastroenterol Dietol. 2008 Jun;54(2):161-76 [18319689.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2081-8 [18461404.001]
  • [Cites] Int J Qual Health Care. 2009 Apr;21(2):137-44 [19147593.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1231-7 [11283921.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22 [11483344.001]
  • [Cites] JAMA. 2002 Oct 16;288(15):1909-14 [12377092.001]
  • [Cites] Mod Pathol. 2003 May;16(5):515-8 [12748259.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] JAMA. 2004 Jun 9;291(22):2720-6 [15187053.001]
  • [Cites] Int J Qual Health Care. 2005 Apr;17(2):141-6 [15665066.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] JAMA. 2010 Mar 17;303(11):1054-61 [20233823.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):317-23 [9440759.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Health Policy. 2003 Sep;65(3):227-41 [12941491.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2346-51 [16998942.001]
  • (PMID = 21358957.001).
  • [ISSN] 1935-469X
  • [Journal-full-title] Journal of oncology practice
  • [ISO-abbreviation] J Oncol Pract
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2988661
  •  go-up   go-down


61. Lin MV, Bishop G, Benito-Herrero M: Diabetic ketoacidosis in type 2 diabetics: a novel presentation of pancreatic adenocarcinoma. J Gen Intern Med; 2010 Apr;25(4):369-73
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabetic ketoacidosis in type 2 diabetics: a novel presentation of pancreatic adenocarcinoma.
  • We report the case of a 75-year-old woman with known type 2 diabetes who presented in DKA and was found to have pancreatic adenocarcinoma.
  • A link between diabetes mellitus and pancreatic cancer has been investigated, but the literature remains inconclusive as to whether diabetes mellitus (DM) is a cause or result of pancreatic cancer or simply the confluence of two common entities.
  • Previous case reports of pancreatic tumors presenting with DKA all represented neuroendocrine tumors.
  • Adenocarcinoma of the pancreas should be considered in the list of precipitants for DKA in type 2 DM.
  • [MeSH-major] Adenocarcinoma / pathology. Diabetes Mellitus, Type 2 / physiopathology. Diabetic Ketoacidosis / physiopathology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1232-8 [10720068.001]
  • [Cites] Biochem Soc Trans. 2008 Oct;36(Pt 5):901-4 [18793158.001]
  • [Cites] Diabetes Res Clin Pract. 2002 Nov;58(2):97-100 [12213350.001]
  • [Cites] Mol Cancer. 2003 Jan 6;2:4 [12556242.001]
  • [Cites] J Clin Invest. 1983 Jun;71(6):1544-53 [6134752.001]
  • [Cites] J Natl Cancer Inst. 1984 May;72(5):1205-8 [6371345.001]
  • [Cites] Diabet Med. 1985 Mar;2(2):113-6 [2952394.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):486-93 [1985741.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):61-6; discussion 66-7 [8380314.001]
  • [Cites] Pancreas. 1994 May;9(3):332-5 [8022755.001]
  • [Cites] JAMA. 1995 May 24-31;273(20):1605-9 [7745774.001]
  • [Cites] Am J Med Sci. 1995 Jun;309(6):326-7 [7771503.001]
  • [Cites] Surgery. 1995 Aug;118(2):453-7; discussion 457-8 [7638764.001]
  • [Cites] J Surg Res. 1996 Jun;63(1):310-3 [8661216.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2585-8 [8669828.001]
  • [Cites] Am J Med. 1996 Jul;101(1):19-24 [8686710.001]
  • [Cites] Pancreas. 1997 Aug;15(2):132-8 [9260197.001]
  • [Cites] Gastroenterology. 1998 Jan;114(1):130-8 [9428227.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):16-24 [10228759.001]
  • [Cites] Langenbecks Arch Surg. 2005 Feb;390(1):66-72 [15083362.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2076-83 [15886696.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):449-54 [15947115.001]
  • [Cites] Clin Chim Acta. 2005 Jul 24;357(2):184-9 [15946661.001]
  • [Cites] Diabet Med. 2005 Oct;22(10):1414-9 [16176205.001]
  • [Cites] Ann Intern Med. 2006 Mar 7;144(5):350-7 [16520476.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):95-101 [18061176.001]
  • [Cites] World J Surg. 2001 Apr;25(4):452-60 [11344398.001]
  • (PMID = 20119682.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2842543
  •  go-up   go-down


62. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ: Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg; 2009 Apr;33(4):716-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen.
  • BACKGROUND: Timely, accurate diagnosis of pancreatic adenocarcinoma (PA) is hampered by the lack of effective circulating biomarkers.
  • The goals of this study were to validate two acute-phase proteins, haptoglobin and serum amyloid A (SAA), as biomarkers for PA and determine if the combination of haptoglobin, SAA, and CA 19-9 would improve PA diagnosis over CA 19-9 alone.
  • METHODS: Levels of haptoglobin, SAA, and CA 19-9 were measured in pretreatment sera from 75 PA patients, 32 patients with chronic pancreatitis, 42 patients with other benign pancreatic disease or biliary stricture, and 150 healthy control subjects by enzyme-linked immunosorbent assay or colorimetric binding assay.
  • This study supports the use of combined biomarkers for improved accuracy in the diagnosis of PA.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Pharm Bull (Tokyo). 1992 Jul;40(7):1847-51 [1394703.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1997 Sep;35(9):647-54 [9352226.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):93-101 [9443988.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):109-12 [9488584.001]
  • [Cites] Schweiz Med Wochenschr. 1999 Jan 23;129(3):77-9 [10065510.001]
  • [Cites] Eur J Biochem. 1999 Oct;265(2):501-23 [10504381.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):442-6 [16428484.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):84-93 [17063306.001]
  • [Cites] Eur J Surg Oncol. 2007 Apr;33(3):266-70 [17097848.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):629-35 [17303689.001]
  • [Cites] Pancreas. 2007 Apr;34(3):310-7 [17414053.001]
  • [Cites] Pancreas. 2007 May;34(4):436-43 [17446843.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):886-91 [17507610.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1774(6):764-71 [17507299.001]
  • [Cites] Clin Chem Lab Med. 2001 Feb;39(2):129-33 [11341746.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2145-51 [11448934.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] FASEB J. 2002 Jul;16(9):1123-5 [12039846.001]
  • [Cites] Int J Exp Pathol. 2003 Apr;84(2):69-74 [12801280.001]
  • [Cites] Int J Oncol. 2003 Sep;23(3):681-91 [12888904.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1720-4 [12973732.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1031-8 [15154618.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):845-56 [15107802.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):379-84 [15241837.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5293; author reply 5293-4 [15297433.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]
  • [Cites] Biochim Biophys Acta. 1987 Feb 14;917(2):219-23 [2879568.001]
  • [Cites] J Clin Oncol. 1988 Mar;6(3):462-8 [3162513.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] Pancreatology. 2007;7(5-6):526-30 [17901713.001]
  • [Cites] J Clin Invest. 1993 Mar;91(3):977-85 [7680672.001]
  • (PMID = 19082654.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA115225-02; United States / NCI NIH HHS / CA / R01 CA115225; United States / NCI NIH HHS / CA / R03 CA115225-02; United States / NCI NIH HHS / CA / P30CA042014; United States / NCI NIH HHS / CA / R13 CA132572; United States / NCI NIH HHS / CA / R03 CA115225; United States / NCI NIH HHS / CA / P30 CA042014
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Haptoglobins; 0 / Serum Amyloid A Protein
  • [Other-IDs] NLM/ NIHMS93122; NLM/ PMC2656575
  •  go-up   go-down


63. Srikureja W, Chang KJ: Endoscopic palliation of pancreatic adenocarcinoma. Curr Opin Gastroenterol; 2005 Sep;21(5):601-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic palliation of pancreatic adenocarcinoma.
  • PURPOSE OF REVIEW: Endoscopic therapies have become an indispensable modality in the treatment and palliation of complications from pancreatic adenocarcinoma.
  • This review focuses on treatment of biliary obstruction, malignant gastric outlet obstruction, and intractable abdominal pain resulting from unresectable pancreatic adenocarcinoma.
  • SUMMARY: The frontier of endoscopic palliative therapies for pancreatic adenocarcinoma is expanding.
  • [MeSH-major] Adenocarcinoma / surgery. Endoscopy, Gastrointestinal. Palliative Care / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093777.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


64. Zins M, Petit E, Boulay-Coletta I, Balaton A, Marty O, Berrod JL: [Imaging of pancreatic adenocarcinoma]. J Radiol; 2005 Jun;86(6 Pt 2):759-79; quiz 779-80
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Imaging of pancreatic adenocarcinoma].
  • [Transliterated title] Imagerie de l'adénocarcinome du pancréas.
  • Pancreatic cancer remains the fourth most common cause of cancer death.
  • Accurate diagnosis and staging are essential for appropriate management of patients with pancreatic cancer.
  • This paper reviews the state of the art for imaging modalities in the diagnosis and staging of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Imaging. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142070.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 108
  •  go-up   go-down


65. Xu J, Liang Z, Hao S, Zhu L, Ashish M, Jin C, Fu D, Ni Q: Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. Abdom Imaging; 2009 Nov;34(6):759-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging.
  • Thus, in lesions of the tissues of the pancreas, this offers to increase the accuracy of CT diagnosis.
  • In this study, our aim was to explore the perfusion characteristics of normal pancreas and pancreatic adenocarcinoma.
  • METHODS: Dynamic 64-slice helical CT was conducted in 36 patients with non-pancreatic disease and in 40 patients with histopathologically proven pancreatic adenocarcinoma.
  • RESULTS: There was no significant difference noted between the distribution of BF, BV, and PS values in different regions of the pancreas, namely the head, neck, body, and tail (P > 0.05).
  • The BF, BV, and PS of normal pancreas were recorded as 135.24 +/- 48.36 ml min(-1) 100 g(-1), 200.55 +/- 54.96 ml 100 g(-1), and 49.75 +/- 24.27 ml min(-1) 100 g(-1), respectively.
  • BF, BV, and PS values of the tumor tissue of pancreatic adenocarcinoma decreased significantly compared to normal pancreas (P < 0.05).
  • CONCLUSIONS: Normal pancreas appears homogenous on perfusion CT.
  • A significant decrease of BF, BV, and PS was observed in pancreatic adenocarcinoma.
  • Dynamic 64-slice helical CT with perfusion imaging should be considered a potential modality to increase the accuracy of CT diagnosis for pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Case-Control Studies. Contrast Media. Female. Humans. Iohexol. Male. Middle Aged. Pancreas / blood supply. Pancreas / radiography. Pancreaticoduodenectomy. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672566.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


66. Shchegolev AI, Dubova EI: [Gastrointestinal stromal tumor of the stomach, concurrent with pancreatic adenocarcinoma]. Arkh Patol; 2007 May-Jun;69(3):48-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumor of the stomach, concurrent with pancreatic adenocarcinoma].
  • The paper presents the data available in the literature and the authors' own data on a concomitance gastrointestinal tumor of the stomach and cancer of the pancreas head, which developed in a 56-year-old patient.
  • A morphological (histological and immunohistochemical) study has established the spindle-cell type of a gastrointestinal tumor that expresses Vimentin, as well as CD 34, CD 117, and pancreatic ductal adenocarcinoma.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722598.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 22
  •  go-up   go-down


67. Zaanan A, Lequoy M, Landi B, Lievre A, Franco D, Taïeb J: Brain metastases from pancreatic adenocarcinoma. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from pancreatic adenocarcinoma.
  • Brain metastases from pancreatic adenocarcinoma (PA) are extremely rare.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2001 Mar;37(3):227-36 [11248578.001]
  • [Cites] J Neuroimmunol. 1998 Aug 14;89(1-2):104-12 [9726832.001]
  • [Cites] Pancreatology. 2006;6(4):306-8 [16636605.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):476-82 [1701858.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Feb;31(2):233-9 [17347640.001]
  • [Cites] Biochem Biophys Res Commun. 1996 May 24;222(3):794-801 [8651925.001]
  • [Cites] Surg Neurol. 2002 Nov;58(5):332-6; discussion 336-7 [12504302.001]
  • [Cites] Virchows Arch. 1996 Nov;429(4-5):191-5 [8972753.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):313-6 [12892239.001]
  • [Cites] Dig Liver Dis. 2004 May;36(5):355-60 [15191206.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):498-503 [17158774.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1663-74 [17363519.001]
  • [Cites] J Mol Med (Berl). 1996 May;74(5):253-68 [8773262.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Jan;30(1):106-9 [16514388.001]
  • (PMID = 21686720.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028083
  •  go-up   go-down


68. Nowak NJ, Gaile D, Conroy JM, McQuaid D, Cowell J, Carter R, Goggins MG, Hruban RH, Maitra A: Genome-wide aberrations in pancreatic adenocarcinoma. Cancer Genet Cytogenet; 2005 Aug;161(1):36-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide aberrations in pancreatic adenocarcinoma.
  • Chromosomal instability, manifesting as copy number alterations (CNAs), is characteristic of pancreatic adenocarcinoma.
  • We used bacterial artificial chromosome (BAC) array-based comparative genomic hybridization (aCGH) to examine the pancreatic adenocarcinoma genome for submicroscopic amplifications and deletions.
  • BAC aCGH proved to be a powerful genome-wide strategy to identify molecular alterations in pancreatic cancer and to distinguish differences between cell line and xenograft aberration profiles.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomal Instability / genetics. Chromosome Aberrations. Chromosomes, Human / genetics. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080956.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 80270; United States / NCI NIH HHS / CA / P30 CA 16056; United States / NCI NIH HHS / CA / P50 CA 62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


69. Ali S, Cohen C, Little JV, Sequeira JH, Mosunjac MB, Siddiqui MT: The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors. Diagn Cytopathol; 2007 Oct;35(10):644-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
  • Pancreatic adenocarcinoma is a genetic disease showing somatic mutations of multiple genes, including SMAD4.
  • SMAD4 is a tumor suppressor gene that is inactivated in a sub-set of pancreatic adenocarcinoma, either by the intragenic mutation of one allele in combination with the loss of the other allele or by homozygous deletion of both alleles.
  • This study examines SMAD4 expression in fine-needle aspiration cell blocks from patients with pancreatic adenocarcinoma, as well as a variety of human cancers, in order to assess its viability as a tumor marker.
  • A total of 100 patients with pancreatic adenocarcinoma, with diagnostic material from fine-needle aspiration cell blocks were selected for this study.
  • SMAD4 staining was nuclear and the results for tumor cell positivity for primary sites studied are as follows: Pancreas (80/100; 80%), endometrium (0/100; 0%), colon (0/100; 0%), ovary (3/100; 3%), lung (0/100; 0%), breast (2/100; 2%), and malignant melanoma (4/100; 4%).
  • This study suggests that SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma as a primary tumor, as well as when it presents as a metastatic tumor on small fine-needle aspirate samples.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism. Smad4 Protein / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17854080.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SMAD4 protein, human; 0 / Smad4 Protein
  •  go-up   go-down


70. Yamada Y, Mori H, Matsumoto S, Kiyosue H, Hori Y, Hongo N: Pancreatic adenocarcinoma versus chronic pancreatitis: differentiation with triple-phase helical CT. Abdom Imaging; 2010 Apr;35(2):163-71
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma versus chronic pancreatitis: differentiation with triple-phase helical CT.
  • BACKGROUND: Chronic pancreatitis and pancreatic adenocarcinoma often show similar clinical and imaging appearances.
  • This study aims to differentiate chronic pancreatitis from pancreatic adenocarcinoma by defining enhancement patterns in both pathologic conditions during triple-phase helical CT.
  • METHODS: The study included 42 patients with chronic pancreatitis and 85 patients with pancreatic adenocarcinoma.
  • RESULTS: Mean contrast enhancement value of normal pancreas peaked in the first phase (early-washout pattern) while that of chronic pancreatitis peaked in the second phase (delayed-washout pattern), and that of pancreatic adenocarcinoma gradually rose (increasing pattern) in both protocols.
  • Diagnostic indices for pancreatic adenocarcinoma were 82.4% and 94.1% for sensitivity, 83% and 83% for specificity, 82.7% and 90.4% for accuracy in protocols A and B, respectively, when differentiation between chronic pancreatitis and pancreatic adenocarcinoma was performed based on time-attenuation curve patterns.
  • CONCLUSION: Our results indicate that time attenuation curves obtained from triple-phase helical CT in protocol B provide useful information in differentiating chronic pancreatitis from pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Pancreatitis / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Chronic Disease. Contrast Media. Diagnosis, Differential. Female. Humans. Iohexol. Iopamidol. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19771464.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; JR13W81H44 / Iopamidol
  •  go-up   go-down


71. Mulkeen AL, Yoo PS, Cha C: Less common neoplasms of the pancreas. World J Gastroenterol; 2006 May 28;12(20):3180-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common neoplasms of the pancreas.
  • Recently, there has been an increased recognition of neoplasms of the pancreas other than ductal adenocarcinoma.
  • Although not as well studied or characterized as pancreatic adenocarcinoma there are many distinct lesions which exhibit diverse biological behaviors and varying degrees of malignancy.
  • These lesions include: endocrine neoplasms, cystic tumors, solid pseudopapillary tumors, acinar cell carcinoma, squamous cell carcinoma, primary lymphoma of the pancreas, and metastatic lesions to the pancreas.
  • This review article discusses the clinical course, diagnosis, and treatment of these less common, but quite relevant, neoplasms of the pancreas.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / therapy. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / therapy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / therapy. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / therapy. Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / therapy. Humans. Lymphoma / diagnosis. Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2002 Apr;160(4):1361-9 [11943721.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):953-62 [11891193.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):675-9 [12167582.001]
  • [Cites] N Engl J Med. 2002 Nov 28;347(22):1783-91 [12456855.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] J Am Coll Surg. 2005 Jun;200(6):965-72 [15922212.001]
  • [Cites] Pancreas. 2005 Aug;31(2):182-7 [16025006.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] J Clin Gastroenterol. 2005 Nov-Dec;39(10):915-9 [16208119.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4518-23 [16002842.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):205-7 [12691166.001]
  • [Cites] Pancreas. 2003 Jul;27(1):e18-22 [12826914.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):859-66 [12912744.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):970-7 [14675706.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):1-18 [15027882.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] J Surg Res. 2004 Jul;120(1):139-61 [15172200.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):898-903 [15198364.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):527-35 [15057558.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1192-6 [7214302.001]
  • [Cites] Surgery. 1990 Sep;108(3):475-80 [2396191.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1329-34 [1678681.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):8-18 [1531004.001]
  • [Cites] Acta Cytol. 1992 Jul-Aug;36(4):471-6 [1636336.001]
  • [Cites] Medicine (Baltimore). 1996 Mar;75(2):53-63 [8606627.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):472-82 [9843608.001]
  • [Cites] Surgery. 1998 Dec;124(6):1050-5 [9854582.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Gastroenterol Clin Biol. 2004 Oct;28(10 Pt 1):872-6 [15523224.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):315-21 [15386314.001]
  • [Cites] AJR Am J Roentgenol. 2005 Feb;184(2):511-9 [15671372.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):512-9 [15767807.001]
  • [Cites] Pancreas. 2005 Apr;30(3):218-22 [15782097.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):124-32 [15827792.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):269-74 [10587182.001]
  • [Cites] J Prosthet Dent. 1999 Nov;82(5):512-4 [10559720.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1668-84 [15887158.001]
  • [Cites] J Am Coll Surg. 2000 Apr;190(4):432-45 [10757381.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):99-103 [10882255.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):237-47 [10962538.001]
  • [Cites] Surgery. 2001 Mar;129(3):380-3 [11231470.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Front Neuroendocrinol. 2001 Oct;22(4):309-39 [11587555.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):35-40 [11833495.001]
  • [Cites] Pancreatology. 2001;1(6):641-7 [12120248.001]
  • (PMID = 16718837.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 51
  • [Other-IDs] NLM/ PMC4087960
  •  go-up   go-down


72. Lowery M, O'Reilly EM: Targeted therapies for pancreatic adenocarcinoma. Minerva Chir; 2009 Oct;64(5):501-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted therapies for pancreatic adenocarcinoma.
  • The majority of patients diagnosed with adenocarcinoma of the pancreas have advanced disease at presentation, with only 20% surviving beyond one year.
  • Systemic therapy for pancreatic adenocarcinoma to date has failed to provide more than a very modest survival benefit for patients with advanced disease.
  • However, the past decade has seen significant advances in the understanding of the molecular pathogenesis of pancreatic cancer, culminating in the sequencing of the pancreatic cancer genome.
  • New generations of therapeutic agents targeting key oncogenic cellular signaling pathways are currently under evaluation in advanced pancreatic adenocarcinoma.
  • Herein the authors review the evidence to date for the use of novel cytotoxic and molecularly targeted agents in pancreatic adenocarcinoma, and discuss key areas for future therapeutic development.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy. ras Proteins / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19859040.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor; EC 2.7.10.2 / src-Family Kinases; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 127
  •  go-up   go-down


73. Bir A, Bshara W, George M, Fakih MG: Idiopathic thrombocytopenic purpura in a newly diagnosed pancreatic adenocarcinoma. JOP; 2006;7(6):647-50
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Idiopathic thrombocytopenic purpura in a newly diagnosed pancreatic adenocarcinoma.
  • CONTEXT: Pancreatic adenocarcinoma presenting as idiopathic thrombocytopenic purpura has not been previously reported in the literature.
  • CASE REPORT: A newly diagnosed patient with metastatic pancreatic adenocarcinoma developed thrombocytopenic purpura prior to initiation of chemotherapy.
  • CONCLUSIONS: ITP can be associated with metastatic pancreatic adenocarcinoma and can respond well to steroid treatment.
  • [MeSH-major] Adenocarcinoma / complications. Pancreatic Neoplasms / complications. Purpura, Thrombocytopenic, Idiopathic / complications. Purpura, Thrombocytopenic, Idiopathic / diagnosis

  • Genetic Alliance. consumer health - Idiopathic thrombocytopenic purpura.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095846.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


74. Reddy SK, Tyler DS, Pappas TN, Clary BM: Extended resection for pancreatic adenocarcinoma. Oncologist; 2007 Jun;12(6):654-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended resection for pancreatic adenocarcinoma.
  • Adenocarcinoma of the pancreas presents a number of therapeutic challenges.
  • TP should not be performed for most cases of adenocarcinoma of the pancreatic head because of the nominal incidence of lymph node involvement along the body and tail of the pancreas, the scarcity of multicentric disease, and the better management of pancreatic leaks after PD.
  • The disappointing experience with extended resections underscores the need for better adjuvant systemic strategies and the interdisciplinary care of patients with pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17602057.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  •  go-up   go-down


75. Mendieta Zerón H, García Flores JR, Romero Prieto ML: Limitations in improving detection of pancreatic adenocarcinoma. Future Oncol; 2009 Jun;5(5):657-68
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limitations in improving detection of pancreatic adenocarcinoma.
  • OBJECTIVE: To review the current trends in pancreatic cancer research and propose alternatives for an earlier diagnosis.
  • METHOD: A search was conducted using the PubMed and Scielo electronic databases to find statistics related to the incidence of pancreatic cancer.
  • RESULTS: Pancreatic cancer is the fourth most common cause of cancer mortality in the USA; in Colombia the incidence of this neoplasia is 4.5 per 100,000 individuals; and in Peru, amongst digestive diseases, it is the fifth most common cause.
  • Chronic pancreatitis, cigarette smoking, diabetes, obesity and dietary mutagen exposure are the most consistent risk factors implicated in the development of pancreatic cancer; however, the genetic and molecular changes underlying the epidemiological association between these factors and pancreatic cancer remain largely unknown, and only 5-10% are hereditary in nature.
  • CONCLUSION: The prognosis for pancreatic cancer has not changed substantially for at least the last 20 years.
  • The most useful tumor marker for pancreatic adenocarcinoma is still the carbohydrate antigen 19-9 (CA19-9).
  • Currently, a multimodal-screening approach of endoscopic ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography are the most effective methods to detect pancreatic cancer in high-risk patients.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519205.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 93
  •  go-up   go-down


76. Al-Refaie WB, Choi EA, Tseng JF, Tamm EP, Lee JH, Lee JE, Evans DB, Pisters PW: Intraductal papillary mucinous neoplasms of the pancreas. Med Princ Pract; 2006;15(4):245-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous neoplasms of the pancreas.
  • The introduction of the exocrine pancreatic classification by the World Health Organization and improvements in pancreatic imaging have led to an improved understanding of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.
  • As a result, IPMNs of the pancreas are increasingly being recognized as a separate disease entity.
  • IPMNs are characterized by the cystic dilatation of the pancreatic duct and its branches, with papillary projections.
  • The lymph nodes are involved considerably less frequently than they are in pancreatic adenocarcinoma.
  • Most patients are symptomatic at diagnosis and require a diagnostic workup similar to that for patients with pancreatic adenocarcinoma.
  • A mural nodule and a main pancreatic duct diameter greater than 5 mm have been found to be predictors of malignancy.
  • [MeSH-major] Adenocarcinoma, Mucinous. Carcinoma, Pancreatic Ductal. Pancreatic Neoplasms

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16763389.001).
  • [ISSN] 1011-7571
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 29
  •  go-up   go-down


77. Germanos S, Gourgiotis S, Stavrothanasopoulou A, Alepas P, Zampitis N, Panteli A: Diagnostic and therapeutic approach to pancreatic adenocarcinoma. J Gastrointestin Liver Dis; 2006 Sep;15(3):257-63
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic approach to pancreatic adenocarcinoma.
  • Pancreatic adenocarcinoma is the sixth leading cause of cancer-related death in Europe with survival rates remaining unchanged over the last three decades.
  • Early diagnosis and accurate staging are essential due to the difficulty of curing this tumor in its advanced form.
  • Endoscopic or laparoscopic ultrasonography and computed tomography are the preferred imaging and staging modalities for many patients with pancreatic adenocarcinoma.
  • This article reviews the causes, risk factors, and clinical features of pancreatic adeno-carcinoma and discusses the methods of optimal diagnosis, staging and treatment.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013451.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 71
  •  go-up   go-down


78. Krempien R, Muenter MW, Harms W, Debus J: Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma. HPB (Oxford); 2006;8(1):22-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma.
  • In spite of the high mortality in pancreatic cancer, significant progress is being made.
  • This review discusses multimodality therapy for patients with pancreatic cancer.
  • Surgical therapy currently offers the only potential monomodal cure for pancreatic adenocarcinoma.
  • Preoperative chemoradiation for potentially resectable pancreatic cancer has the following advantages:.
  • This review systematically summarizes the current status, controversies, and prospects of neoadjuvant treatment of pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Aug 1;78(3 Suppl):598-604 [8681298.001]
  • [Cites] Radiother Oncol. 2004 Sep;72(3):257-66 [15450723.001]
  • [Cites] Langenbecks Arch Surg. 2005 Apr;390(2):94-103 [15578211.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3587-96 [15867264.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4538-44 [16002845.001]
  • [Cites] Eur J Cancer. 2005 Oct;41(15):2213-36 [16146690.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):71-7; discussion 77-8 [7818001.001]
  • [Cites] Chirurg. 1994 Dec;65(12):1111-5 [7851144.001]
  • [Cites] Arch Surg. 1994 Oct;129(10):1075-80 [7944938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7 [8083109.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):118-24; discussion 124-5 [8554125.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):317-23 [9440759.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):116-20 [9641883.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1328-34 [9762933.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3843-50 [9850029.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):393-400 [10077052.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 4:291-5 [10436843.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Arch Surg. 2000 Jan;135(1):81-7; discussion 88 [10636353.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):314-27 [10918161.001]
  • [Cites] J Gastrointest Surg. 2001 Jan-Feb;5(1):27-35 [11309645.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2246-53 [11489798.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):933-8 [11490843.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):758-65 [11776488.001]
  • [Cites] Med Dosim. 2002 Summer;27(2):121-9 [12074463.001]
  • [Cites] Oncology (Williston Park). 2003 Dec;17(12 Suppl 13):29-36 [14723004.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7 [12422311.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):30-6 [12576921.001]
  • [Cites] Strahlenther Onkol. 2003 Feb;179(2):78-86 [12590317.001]
  • [Cites] Chirurg. 2003 Mar;74(3):202-7 [12647076.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1300-4 [12654441.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 9):71-9 [12908138.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Arch Surg. 1992 Nov;127(11):1335-9 [1359851.001]
  • [Cites] Oncology (Williston Park). 2003 Dec;17(12 Suppl 13):23-8 [14723003.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Feb;4(1):53-60 [14748657.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]
  • [Cites] Am J Clin Oncol. 2004 Aug;27(4):343-9 [15289726.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S69-77 [15316751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52 [15380578.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2485-91 [8952555.001]
  • (PMID = 18333234.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2131366
  •  go-up   go-down


79. Balachandran A, Darden DL, Tamm EP, Faria SC, Evans DB, Charnsangavej C: Arterial variants in pancreatic adenocarcinoma. Abdom Imaging; 2008 Mar-Apr;33(2):214-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arterial variants in pancreatic adenocarcinoma.
  • Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma.
  • Unexpected variant arterial anatomy or tumor involvement of aberrant arteries may complicate pancreatic surgery.
  • We describe here the arterial variant anatomy of the pancreas and its identification by multidetector CT imaging, with and without the aid of post-processed volume-rendered images.
  • [MeSH-major] Adenocarcinoma / blood supply. Celiac Artery / abnormalities. Mesenteric Arteries / abnormalities. Pancreas / blood supply. Pancreatic Neoplasms / blood supply

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17435979.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 22
  •  go-up   go-down


80. Gupta N, Krishnan PV, Muzaffar J, Arora A, Anuradha S, Gondal R, Agarwal A, Kar P: Cystic ductal adenocarcinoma of pancreas: an unusual variant. Trop Gastroenterol; 2006 Jul-Sep;27(3):131-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic ductal adenocarcinoma of pancreas: an unusual variant.
  • Cystic lesions of the pancreas are usually pseudocysts (90%); only 10% of them are cystic tumors.
  • These cystic tumors constitute less than 10% of all pancreatic neoplasms, making them an extremely uncommon type of pancreatic malignancy.
  • Ductal adenocarcinoma of pancreas presenting in cystic form is an uncommon type of cystic tumor, making it extremely rare among all pancreatic malignancies (solid or cystic).
  • The review of literature concerning the diagnosis and management has also been discussed.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17310557.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


81. Dennis MM, O'Brien TD, Wayne T, Kiupel M, Williams M, Powers BE: Hyalinizing pancreatic adenocarcinoma in six dogs. Vet Pathol; 2008 Jul;45(4):475-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinizing pancreatic adenocarcinoma in six dogs.
  • Exocrine pancreatic carcinoma is a particularly malignant neoplasm of the dog.
  • Clinical and pathologic findings of an unusual variant of exocrine pancreatic neoplasia termed hyalinizing pancreatic adenocarcinoma were evaluated in 6 dogs.
  • Two patients survived longer than 15 months after diagnosis; one of these dogs was untreated and had grossly evident metastasis at the time of diagnosis.
  • Two dogs were diagnosed with panniculitis, a condition rarely associated with pancreatic disease.
  • Studies that associate exocrine pancreatic carcinoma grade and histologic subtype with prognostic outcomes in the dog are warranted such that appropriate therapy can be elected.
  • [MeSH-major] Adenocarcinoma / veterinary. Dog Diseases / metabolism. Hyalin / metabolism. Pancreatic Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18587093.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Zhao H, Mandich D, Cartun RW, Ligato S: Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol; 2007 Nov;35(11):700-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas.
  • We evaluated the immunocytochemical (ICC) expression of K homology domain containing protein overexpressed in cancer (KOC) in pancreatic endoscopic ultrasound-guided fine needle aspirates (EUS-FNAs) to assess its potential use as an adjunct in differentiating nonneoplastic (GI epithelium) and benign neoplastic epithelia (benign epithelial pancreatic neoplasms) from pancreatic adenocarcinoma cells.
  • We conclude that KOC ICC expression on alcohol-fixed smears along with cytology improves the sensitivity of EUS-FNAs in the diagnosis of pancreatic Ac, and KOC reactivity is especially useful in differentiating Ac from nonneoplastic gastrointestinal epithelium and benign neoplastic epithelia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biopsy, Fine-Needle. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Endosonography. Female. Humans. Male. Middle Aged. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17924416.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


83. Torer N, Kayaselcuk F, Nursal TZ, Yildirim S, Tarim A, Nòyan T, Karakayali H: Adhesion molecules as prognostic markers in pancreatic adenocarcinoma. J Surg Oncol; 2007 Oct 1;96(5):419-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adhesion molecules as prognostic markers in pancreatic adenocarcinoma.
  • BACKGROUND AND OBJECTIVES: Pancreatic adenocarcinoma is a highly aggressive cancer with high metastatic potential and therefore, a high mortality rate.
  • In this study, we investigated the relationship of ezrin, moesin, and E-cadherin expression with the clinicopathological features of pancreatic ductal adenocarcinoma.
  • Only moesin was correlated with survival in resected pancreatic adenocarcinomas and moesin-negative patients had longer survivals compared with moesin-positive patients (P = 0.021).
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17874463.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cytoskeletal Proteins
  •  go-up   go-down


84. Thayalasekaran S, Liddicoat H, Wood E: Thrombophlebitis migrans in a man with pancreatic adenocarcinoma: a case report. Cases J; 2009;2:6610

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombophlebitis migrans in a man with pancreatic adenocarcinoma: a case report.
  • It is an acquired coagulopathy that is strongly associated with malignancy, especially solid tumours of the adenocarcinoma type.
  • Ultrasound demonstrated a mass in the head of the pancreas causing common bile duct obstruction.
  • Histology confirmed pancreatic adenocarcinoma.
  • CONCLUSION: Thrombophlebitis migrans is more easily recognised in patients with an established diagnosis of malignancy than in situations where the thrombophlebitis is first diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Dermatol. 1993 Jan-Mar;11(1):159-63 [8339192.001]
  • [Cites] Haemostasis. 1997;27 Suppl 1:38-43 [9439757.001]
  • [Cites] Thromb Haemost. 2006 Mar;95(3):541-5 [16525584.001]
  • [Cites] J Clin Invest. 2003 Sep;112(6):853-62 [12975470.001]
  • [Cites] Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21 [12814981.001]
  • (PMID = 19829832.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2709970
  •  go-up   go-down


85. Deshmukh SD, Willmann JK, Jeffrey RB: Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: evaluation with 3D volume-rendered MDCT imaging. AJR Am J Roentgenol; 2010 Mar;194(3):668-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathways of extrapancreatic perineural invasion by pancreatic adenocarcinoma: evaluation with 3D volume-rendered MDCT imaging.
  • OBJECTIVE: The purpose of this article is to familiarize radiologists with the common pathways of extrapancreatic perineural invasion of pancreatic adenocarcinoma and to highlight the potential value of 3D volume-rendered MDCT in its diagnosis.
  • CONCLUSION: The perineural plexuses closely follow peripancreatic vessels, which are well depicted by contrast-enhanced 3D volume-rendered imaging, thus facilitating the diagnosis of extrapancreatic perineural invasion of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Imaging, Three-Dimensional. Neoplasm Invasiveness / pathology. Pancreatic Neoplasms / pathology. Peripheral Nervous System Neoplasms / pathology. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173143.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Jin G, Hu XG, Ying K, Tang Y, Liu R, Zhang YJ, Jing ZP, Xie Y, Mao YM: Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays. World J Gastroenterol; 2005 Nov 7;11(41):6543-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays.
  • AIM: To study the pathogenetic processes and the role of gene expression by microarray analyses in expediting our understanding of the molecular pathophysiology of pancreatic adenocarcinoma, and to identify the novel cancer-associated genes.
  • METHODS: Nine histologically defined pancreatic head adenocarcinoma specimens associated with clinical data were studied.
  • In pancreatic adenocarcinoma tissue, several invasion and metastasis related genes showed their high expression levels, suggesting that poor prognosis of pancreatic adenocarcinoma might have a solid molecular biological basis.
  • CONCLUSION: The application of cDNA microarray technique for analysis of gene expression patterns is a powerful strategy to identify novel cancer-associated genes, and to rapidly explore their role in clinical pancreatic adenocarcinoma.
  • Microarray profiles provide us new insights into the carcinogenesis and invasive process of pancreatic adenocarcinoma.
  • Our results suggest that a highly organized and structured process of tumor invasion exists in the pancreas.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425432.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4355802
  •  go-up   go-down


87. Rana SS, Bhasin DK, Jain K, Nada R, Sinha SK, Singh K: Endoscopic diagnosis of squamous cell carcinoma of the pancreas invading the stomach. JOP; 2009;10(2):181-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic diagnosis of squamous cell carcinoma of the pancreas invading the stomach.
  • CONTEXT: Squamous cell carcinoma of the pancreas is an unusual tumor due to the absence of squamous cells in the normal pancreas.
  • Its clinical presentation is similar to that of adenocarcinoma of the pancreas and is usually diagnosed intraoperatively or at autopsy.
  • Contrast-enhanced computerized tomography revealed a heterogeneous enhancing mass in the head of pancreas and upper gastrointestinal endoscopy revealed an ulcerated polypoidal lesion in the stomach; the endoscopic biopsies taken from this region revealed infiltration of the lamina propria with malignant squamous cells.
  • CONCLUSION: A rare case of squamous cell carcinoma of the head of the pancreas presenting with obstructive jaundice and gastric outlet obstruction and in which diagnosis was established by endoscopic biopsies of the stomach has been described.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Pancreatic Neoplasms / diagnosis. Stomach / pathology
  • [MeSH-minor] Diagnosis, Differential. Endoscopy, Gastrointestinal. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Stomach carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287113.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


88. Mirarchi M, De Raffele E, Lega S, Calculli L, Vaccari S, Cola B: [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient]. Chir Ital; 2009 May-Jun;61(3):357-67
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient].
  • [Transliterated title] Adenocarcinoma del colon e neoplasia papillare intraduttale mucinosa multifocale sincrona del pancreas in un paziente anziano: caso clinico e revisione della letteratura.
  • Intraductal papillary mucinous neoplasms are a well-recognized pathologic entity of the pancreas that is being reported with increasing frequency.
  • A 78-year-old man presented with rectal bleeding which led to the diagnosis of a stenosing adenocarcinoma of the sigmoid colon.
  • No metastatic lesions were present but a 30 mm intraductal papillary mucinous neoplasm with mural nodules was detected in the uncinate process of the pancreas.
  • The co-existence of a potentially malignant pancreatic tumour with an extra-pancreatic overt malignancy in elderly patients poses difficulties in the attempt to cure the patient with minimal morbidity.
  • In the present case we considered a staged surgical procedure with the aim of reducing the perioperative risk, since the excision of the pancreatic neoplasm required a pancreaticoduodenectomy in an elderly patient.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694240.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


89. Dembinski JL, Krauss S: A Distinct Slow-Cycling Cancer Stem-like Subpopulation of Pancreatic Adenocarcinoma Cells is maintained in Vivo. Cancers (Basel); 2010;2(4):2011-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Distinct Slow-Cycling Cancer Stem-like Subpopulation of Pancreatic Adenocarcinoma Cells is maintained in Vivo.
  • Pancreatic adenocarcinoma has the worst prognosis of any major malignancy, with.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24281215.001).
  • [ISSN] 2072-6694
  • [Journal-full-title] Cancers
  • [ISO-abbreviation] Cancers (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3840458
  •  go-up   go-down


90. Ausania F, Caricato M, Borzomati D, Giarratano G, Garberini A, Rosignoli A, Ripetti V, Tonini G, Coppola R: [Cerebellar metastasis from pancreatic adenocarcinoma: report of a clinical case]. Suppl Tumori; 2005 May-Jun;4(3):S62
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cerebellar metastasis from pancreatic adenocarcinoma: report of a clinical case].
  • [Transliterated title] Metastasi cerebellare da adenocarcinoma del pancreas descrizione di un caso clinico.
  • We describe a case of a metacronous cerebellar metastasis from pancreatic adenocarcinoma occurred in a 67 years old male.
  • Central nervous system metastases from pancreatic carcinoma are mostly autoptic findings.
  • To our knowledge, this is the first case reported in literature of cerebellar metastasis from pancreatic cancer; furthermore, this case calls attention on vomit presentation that could be erroneously attributed to an abdominal relapse.
  • [MeSH-major] Adenocarcinoma / secondary. Cerebellar Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437906.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


91. Rudloff U, Maker AV, Brennan MF, Allen PJ: Randomized clinical trials in pancreatic adenocarcinoma. Surg Oncol Clin N Am; 2010 Jan;19(1):115-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized clinical trials in pancreatic adenocarcinoma.
  • This article critically reviews and ranks 107 prospective, randomized controlled trials (RCT) for pancreatic adenocarcinoma published between 2000 and 2008 identified through a standard MEDLINE literature search strategy, according to a standardized, previously published 3-tiered system (Ia, Ib, and Ic).
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy. Randomized Controlled Trials as Topic

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19914563.001).
  • [ISSN] 1558-5042
  • [Journal-full-title] Surgical oncology clinics of North America
  • [ISO-abbreviation] Surg. Oncol. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 128
  •  go-up   go-down


92. Ichikawa T, Erturk SM, Sou H, Nakajima H, Tsukamoto T, Motosugi U, Araki T: MDCT of pancreatic adenocarcinoma: optimal imaging phases and multiplanar reformatted imaging. AJR Am J Roentgenol; 2006 Dec;187(6):1513-20
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDCT of pancreatic adenocarcinoma: optimal imaging phases and multiplanar reformatted imaging.
  • OBJECTIVE: The objective of our study was to evaluate the individual contributions of arterial, pancreatic parenchymal, and portal venous phase (PVP) images and the utility of coronal and sagittal multiplanar reformatted (MPR) images in the assessment of pancreatic adenocarcinoma using triple-phase MDCT.
  • MATERIALS AND METHODS: Thirty-one patients with and 35 patients without pancreatic adenocarcinoma underwent triple-phase MDCT.
  • Three radiologists independently attempted to detect pancreatic adenocarcinoma and assess local extension using the MDCT images in five sessions.
  • The first three sessions involved sets of images obtained in arterial phase, pancreatic parenchymal phase, and PVP separately and respectively.
  • CONCLUSION: A combination of pancreatic parenchymal phase and PVP imaging is necessary and efficient for the assessment of pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114545.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH: PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res; 2007 Dec 15;13(24):7380-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
  • PURPOSE: The anti-MUC1 monoclonal antibody (MAb), PAM4, has a high specificity for pancreatic adenocarcinoma compared with other cancers, normal tissues, or pancreatitis.
  • In order to assess its role in early pancreatic cancer development, we examined the expression of the PAM4-reactive MUC1 in the noninvasive precursor lesions, pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasia (IPMN).
  • RESULTS: The PAM4-reactive MUC1 epitope was not detected in normal pancreas but was expressed in 87% (48 of 55) of invasive pancreatic adenocarcinomas, including early stage 1 disease: PAM4 labeled 94% (44 of 47) of the earliest PanIN lesions, PanIN-1A and 1B, along with 91% (10 of 11) of PanIN-2, 40% (2 of 5) of PanIN-3, and 86% (31 of 36) of intraductal papillary mucinous neoplasia lesions.
  • A second, unrelated, anti-MUC1 MAb, MA5, showed considerably less sensitivity with early PanIN-1 lesions; only 61% (25 of 41) were positive and the labeling did not differentiate normal pancreas from PanINs.
  • CONCLUSIONS: The results suggest that expression of the PAM4-reactive antigen may represent an early event in the development of invasive pancreatic adenocarcinoma, and is unrelated to the VNTR peptide core epitopes of MUC1.
  • Detection of this biomarker using immunohistology, in vitro immunoassays, and in vivo antibody-based imaging may provide new opportunities for the early detection and improved diagnosis of pancreatic cancer.
  • [MeSH-major] Antibodies, Monoclonal. Biomarkers, Tumor / analysis. Carcinoma in Situ / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Mucin-1 / metabolism. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2008 Aug 15;14(16):5306; author reply 5306-7 [18698052.001]
  • (PMID = 18094420.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA096924; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Mucin-1
  •  go-up   go-down


94. Paspulati RM: Multidetector CT of the pancreas. Radiol Clin North Am; 2005 Nov;43(6):999-1020, viii
MedlinePlus Health Information. consumer health - Pancreatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidetector CT of the pancreas.
  • CT is the primary imaging modality of the pancreas.
  • This article reviews the multidector CT technique and its current status in the diagnosis of various pancreatic diseases.
  • Special emphasis is given to the impact of multidetector CT and postprocessing imaging techniques on the staging of pancreatic adenocarcinoma.
  • [MeSH-major] Pancreatic Diseases / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253659.001).
  • [ISSN] 0033-8389
  • [Journal-full-title] Radiologic clinics of North America
  • [ISO-abbreviation] Radiol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 106
  •  go-up   go-down


95. Schima W, Ba-Ssalamah A, Kölblinger C, Kulinna-Cosentini C, Puespoek A, Götzinger P: Pancreatic adenocarcinoma. Eur Radiol; 2007 Mar;17(3):638-49
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma.
  • Adenocarcinoma is the most common malignant pancreatic tumor, affecting the head of the pancreas in 60-70% of cases.
  • By the time of diagnosis, at least 80% of tumors are unresectable.
  • Helical computed tomography (CT) is very effective in detecting and staging adenocarcinoma, with a sensitivity of up to 90% for detection and an accuracy of 80-90% for staging, but it has limitations in detecting small cancers.
  • MDCT has been found to be at least equivalent to contrast-enhanced magnetic resonance imaging (MRI) for detecting adenocarcinoma.
  • Mangafodipir-enhanced MRI reveals a very high tumor-pancreas contrast, which helps in diagnosing small cancers.
  • It is the technique of choice for image-guided biopsy if a histologic diagnosis is required for further therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Mar;214(3):849-55 [10715057.001]
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] Eur Radiol. 2004 Jan;14(1):14-20 [14730384.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):218-24 [12145600.001]
  • [Cites] Abdom Imaging. 1997 Jul-Aug;22(4):429-33 [9157866.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10 ):753-63 [15545675.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Abdom Imaging. 1997 Mar-Apr;22(2):204-7 [9013536.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):700-3 [16120921.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Pancreatology. 2001;1(6):610-24 [12120244.001]
  • [Cites] AJR Am J Roentgenol. 1998 Mar;170(3):649-52 [9490946.001]
  • [Cites] Eur Radiol. 2005 Nov;15 Suppl 4:D96-9 [16479656.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):231-4 [11246351.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiology. 1997 Nov;205(2):513-8 [9356637.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1410-27 [15499648.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):118-26; discussion 127-8 [12559193.001]
  • [Cites] Radiology. 1991 Aug;180(2):337-9 [1906189.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):619-23 [14975959.001]
  • [Cites] Br J Radiol. 2000 Nov;73(875):1165-9 [11144793.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Radiology. 1993 Mar;186(3):795-8 [8430190.001]
  • [Cites] Radiographics. 2005 Jul-Aug;25(4):949-65 [16009817.001]
  • [Cites] Radiology. 2001 Oct;221(1):107-16 [11568327.001]
  • [Cites] AJR Am J Roentgenol. 1999 Dec;173(6):1513-8 [10584794.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1315-22 [9574609.001]
  • [Cites] Eur Radiol. 2005 Jun;15(6):1256-62 [15627187.001]
  • [Cites] Radiology. 2002 Sep;224(3):764-8 [12202711.001]
  • [Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]
  • [Cites] Invest Radiol. 1999 Sep;34(9):589-95 [10485075.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):494-504 [7960219.001]
  • [Cites] Br J Radiol. 1998 May;71(845):492-6 [9691893.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 5:M42-9 [14989611.001]
  • [Cites] Radiology. 2002 Dec;225(3):759-65 [12461258.001]
  • [Cites] Radiology. 1998 Feb;206(2):373-8 [9457188.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):119-23 [9207510.001]
  • [Cites] Radiology. 1991 Jan;178(1):95-9 [1984331.001]
  • [Cites] Eur Radiol. 1996;6(1):14-8 [8797944.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):677-84 [10701608.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12 ):2658-61 [16393216.001]
  • [Cites] Eur Radiol. 2002 Dec;12(12):2998-3008 [12439582.001]
  • [Cites] Radiology. 2006 Nov;241(2):441-8 [16982815.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):419-25 [14736675.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):230-3 [2154172.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Radiology. 1997 Mar;202(3):655-62 [9051012.001]
  • [Cites] J Magn Reson Imaging. 2000 Aug;12 (2):261-8 [10931589.001]
  • [Cites] Radiology. 1995 May;195(2):327-32 [7724748.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1439-43 [9168704.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):738-45 [15492552.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] World J Surg. 1999 Sep;23(9):913-9 [10449820.001]
  • [Cites] Rofo. 2004 Nov;176(11):1624-33 [15497081.001]
  • [Cites] J Comput Assist Tomogr. 2002 Sep-Oct;26(5):743-9 [12439309.001]
  • [Cites] Radiology. 1995 Nov;197(2):381-5 [7480681.001]
  • [Cites] Radiology. 2001 Jul;220(1):97-102 [11425979.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • (PMID = 17021700.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 65
  •  go-up   go-down


96. Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, Schulick RD, Pawlik TM: Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer; 2007 Dec 1;110(11):2484-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?
  • Specifically, the role of hepatic resection for metastatic periampullary or pancreatic adenocarcinoma remains controversial.
  • METHODS: Between 1995 and 2005, 1563 patients underwent surgical resection for periampullary carcinoma (n=608 patients) or pancreatic adenocarcinoma (head, n=905 patients; tail, n=50 patients).
  • RESULTS: Of the 1563 patients who underwent resection of periampullary or pancreatic adenocarcinoma, 22 patients (1.4%) underwent simultaneous hepatic resection for synchronous liver metastasis.
  • The primary tumor site was ampullary (n=1 patient ), duodenal (n=2 patients), distal bile duct (n=2 patients), or pancreas (head, n=10 patients; tail, n=7 patients).
  • Pancreatic (median, 5.9 months) versus nonpancreatic (median, 9.9 months) primary tumor histology was not associated with a difference in survival in patients who underwent resection of synchronous liver metastasis (P=.43).
  • CONCLUSIONS: Even in well selected patients with low-volume metastatic liver disease, simultaneous resection of periampullary or pancreatic carcinoma with synchronous liver metastases did not result in long-term survival in the overwhelming majority of patients.
  • [MeSH-major] Adenocarcinoma / surgery. Liver Neoplasms / secondary. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17941009.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Salles A, Nino-Murcia M, Jeffrey RB Jr: CT of pancreas: minimum intensity projections. Abdom Imaging; 2008 Mar-Apr;33(2):207-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT of pancreas: minimum intensity projections.
  • OBJECTIVE: The purpose of this pictorial essay is to showcase the use of minimum intensity projection in the imaging of low attenuation structures such as the pancreatic duct.
  • CONCLUSION: Minimum intensity projection is a valuable adjunct to other processing techniques for the diagnosis and staging of pancreatic adenocarcinoma and cystic tumors of the pancreas.
  • [MeSH-major] Pancreas / radiography. Pancreatic Diseases / diagnosis. Pancreatic Neoplasms / diagnosis. Tomography, Spiral Computed / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387537.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 9
  •  go-up   go-down


98. Misek DE, Kuick R, Hanash SM, Logsdon CD: Oligonucleotide-directed microarray gene profiling of pancreatic adenocarcinoma. Methods Mol Med; 2005;103:175-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligonucleotide-directed microarray gene profiling of pancreatic adenocarcinoma.
  • In this chapter we describe our approach to the profiling of pancreatic adenocarcinoma to illustrate the various steps and methods involved in this type of study.
  • Pancreatic adenocarcinoma is a particularly challenging subject for gene profiling, as these tumors have a profound desmoplastic response such that neoplastic epithelium makes up only a small proportion of the tissue mass.
  • We have utilized statistical comparisons of gene expression between adenocarcinoma, normal pancreas, samples of chronic pancreatitis, and pancreatic cancer cell lines that provides a means to deduct the influence of the stromal elements.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15542906.001).
  • [ISSN] 1543-1894
  • [Journal-full-title] Methods in molecular medicine
  • [ISO-abbreviation] Methods Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides
  •  go-up   go-down


99. Sebens Müerköster S, Kötteritzsch J, Geismann C, Gast D, Kruse ML, Altevogt P, Fölsch UR, Schäfer H: alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma. Int J Oncol; 2009 Jan;34(1):243-53
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma.
  • We recently showed that the adhesion molecule L1CAM (CD171) is overexpressed in pancreatic adenocarcinoma (PDAC) essentially contributing to chemoresistance of PDAC cells.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Drug Resistance, Neoplasm. Integrin alpha5 / physiology. Neural Cell Adhesion Molecule L1 / metabolism. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082495.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Integrin alpha5; 0 / Neural Cell Adhesion Molecule L1; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 6PLQ3CP4P3 / Etoposide; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 3.4.22.- / Caspases
  •  go-up   go-down


100. Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME: BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol; 2009 Jan 20;27(3):433-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
  • PURPOSE: The prognostic significance of germline BRCA1 and BRCA2 mutations in Jewish patients with pancreatic adenocarcinoma (PAC) is unknown.
  • The BRCA2 founder mutation was identified in 4.1% of patients with pancreatic adenocarcinoma compared with only 1.1% of cancer-free Washington, DC,-area controls (4.1% v 1.1%; P = .007; odds ratio, 3.85; 95% CI, 2.1 to 10.8).
  • [MeSH-major] Adenocarcinoma / genetics. Genes, BRCA1. Genes, BRCA2. Jews / genetics. Mutation. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] Br J Cancer. 1999 Aug;80(11):1830-7 [10468306.001]
  • [Cites] Cancer Biol Ther. 2005 Sep;4(9):934-6 [16251802.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3946-52 [16921047.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 6;98(23):1675-7 [17148764.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] J Gastroenterol Hepatol. 2007 May;22(5):738-48 [17444865.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):701-6 [18027062.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):409-16 [10667595.001]
  • [Cites] JAMA. 2000 May 3;283(17):2260-5 [10807385.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73 [11352856.001]
  • [Cites] Cell. 2002 Jan 25;108(2):171-82 [11832208.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] Gut. 2002 May;50(5):653-7 [11950811.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3789-93 [12097290.001]
  • [Cites] Pancreatology. 2001;1(5):466-71 [12120226.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65 [12237281.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72 [12237282.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3776-81 [12473589.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4222-7 [14615451.001]
  • [Cites] Oncologist. 2004;9(1):13-24 [14755011.001]
  • [Cites] J Natl Cancer Inst. 1986 Jan;76(1):49-60 [3455742.001]
  • [Cites] Nebr Med J. 1989 May;74(5):109-12 [2542813.001]
  • [Cites] Br J Cancer. 1990 Jun;61(6):932-6 [2372499.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Nature. 1994 Mar 17;368(6468):258-61 [8145827.001]
  • [Cites] J Med Genet. 1994 Aug;31(8):618-21 [7815419.001]
  • [Cites] Hum Mol Genet. 1994 Sep;3(9):1679-82 [7833928.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):392-8 [7894492.001]
  • [Cites] JAMA. 1995 May 24-31;273(20):1605-9 [7745774.001]
  • [Cites] Gastroenterology. 1995 Jul;109(1):247-51 [7797022.001]
  • [Cites] Am J Hum Genet. 1995 Jul;57(1):189 [7611288.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):970-4 [7666916.001]
  • [Cites] Nat Genet. 1995 Oct;11(2):198-200 [7550349.001]
  • [Cites] Epidemiology. 1995 Sep;6(5):498-502 [8562625.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5360-4 [8968085.001]
  • [Cites] N Engl J Med. 1997 May 15;336(20):1401-8 [9145676.001]
  • [Cites] Nat Genet. 1997 May;16(1):17-8 [9140390.001]
  • [Cites] Lancet. 1997 Jul 12;350(9071):117-8 [9228974.001]
  • [Cites] JAMA. 1997 Oct 15;278(15):1242-50 [9333265.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):67-91 [9443987.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1839-42 [9581822.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1642-9 [9586873.001]
  • [Cites] Am J Hum Genet. 1999 Apr;64(4):963-70 [10090881.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6 [10433620.001]
  • [Cites] Genet Test. 1997;1(1):47-51 [10464625.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7529-35 [16234519.001]
  • (PMID = 19064968.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3657622
  •  go-up   go-down






Advertisement